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2. Introduction and Personal Perspective 
 
My public works are a combination of a number of varied examples that when 
combined demonstrate that during my 26 year career I have not only contributed to but 
have significantly affected daily practice by implementing innovation more effectively 
within the non-invasive medical devices field. In the following sections I will reflect on 
these public works and in context outline how through both institutional and work 
based learning I gained and imparted new knowledge to my field of expertise. I will 
explore the barriers to successful implementation of innovation and will elaborate on 
the specific challenges faced as I transitioned within, and between organizations and up 
the leadership ladder. I will explore how I overcame these varied challenges and created 
new opportunities along the way implementing a number of innovative products into 
the global marketplace. I will demonstrate how I established and managed innovative 
organizations with virtual structured teams of uniquely competent professionals across 
dispersed geographic locations, encompassing the required expertise in all the highly 
technical and clinical areas needed to allow for more effective implementation of 
complex medical products. I will then expand this discussion further to evidence my 
more effective implementation of a number of innovations. Furthermore, I will illustrate 
my progression and provide examples of my journey to becoming a pragmatic 
entrepreneur. I will conclude by detailing and critiquing my unique contribution to the 
field, supporting my claim that I have; ‘Implemented innovation more effectively within 
the highly regulated non-invasive medical device field’.  
 
2.1.  My early background  
 
From as early as comprehensive school I’ve had a keen realization that I needed to 
broaden my knowledge base in order to be successful in life. Coming from a poor 
working-class family as the middle child of seven, it was clearly evident that in order to 
make a success of my life that I would need to forge my own path. After completing 
school I entered the work pool and spent the next six months as a manual labourer on 
one of the local nurseries in West Sussex. I recall starting my days at four in the morning 
in the freezing cold harvesting lettuce for market with a knife. Although manual labour 
was nothing new to me, the harshness of this endeavour for the measly returns I would 
earn was one of my first examples of on-the-job learning. I learnt during this time that; 
hard physical work was nothing to be ashamed of, that comradeship and a positive 
attitude made the work seem easier, and most importantly, that clearly this was not the 
career path I wanted to pursue long-term. Consequentially, I went back to technical 
college to study for an Ordinary National Diploma in engineering. 
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I re-entered the workforce in 1986 and was employed initially as a service engineer at 
the European headquarters of an American medical device conglomerate focused in the 
respiratory and ventilator fields based in London, and became immersed in learning my 
new trade. This workplace learning involved hands-on instruction, such that you might 
expect in a traditional apprenticeship, combined with a significant amount of classroom 
learning taught by my manager. As part of company structured education I was also sent 
to attend in-depth product related training at the company’s factories in the United 
States. These early trips went a long way in solidifying my career path, as not only did I 
realize that I had a yearning to learn as much as possible about this exciting field, but I 
also came to appreciate the importance of gaining different perspectives from around 
the world.  During this period I also took advantage of the company-sponsored 
continuing education program and completed a Higher National Certificate in 
Engineering. After earning the respect of my peers by my hard work and an insatiable 
appetite to be involved, I was given the opportunity of taking over the technical 
education responsibilities for European operations of the company. These were my first 
evolutionary steps as an educator. I fondly look back at these early days, as this is when I 
started to appreciate the importance of continued learning and also honed my 
presentation and teaching skills. My time was now increasingly spent furthering my 
knowledge about the respiratory and ventilator field, the technical and clinical aspects 
of the company's current and new products, and then assimilating this new knowledge 
into various training courses which usually were between 3 to 5 days in duration. This 
involved drafting pre-study material (Griffiths & Canfield, 1993)1 that brought all 
students up to the same starting point prior to attending my classes, as well as 
developing detailed training manuals that involved both classroom learning and hands-
on workshops. The majority of my classes were evaluated by the students with 
effectiveness matrices being kept to provide input into content and for delivery 
improvement. The classes also involved assessment of the student’s learning by daily 
tests and final examination that included many practical hands-on elements. I found 
that many of the teaching approaches I had encountered could be improved upon in 
order to gain greater knowledge transfer and enjoyment of the learning process for 
both the students and teacher alike. I think this interdisciplinary co-dependency was 
aptly described early on by Dr. Karl Rosenkranz in his book Pedagogics as a System 
(1872, p. 5) when he states "it (the art of teaching) is rather a mixed science which has 
its presuppositions in many others. In this respect it resembles medicine." An 
interrelationship that is particularly poignant in my particular instance.  
                                                            
1 These pre-study booklets are still being used in predominantly the same form today by the company as the core 
physiological and mechanical ventilator concepts and science is the same.   
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Over the next four years, I refined my craft and taught classes to hundreds of learners 
from across the globe, sometimes at offices in London but in many cases internationally. 
I frequently travelled and conducted well over one hundred technical and clinical 
seminars on every continent. As a young professional this was incredibly exciting and 
provided me with a strong grounding in not just the core competences of my profession, 
but equally importantly, in the varied cultures and approaches to healthcare from across 
the globe. I found that the thirst for knowledge and desire to do a good job was 
universal. Even if the political and environmental situations did everything to discourage 
such ideals. I recall one specific incident that brought this point home. On my first visit 
to Moscow in 1986, when things were still well under the Soviet era regime, I was 
lecturing at the Bakoulev Cardiac Institute (2012), utilizing a presentation that I had used 
many timed before which was on a specific form of ventilation which required utilizing 
aggressive hemodynamic support from a type of drug called vasopressors.2 Suddenly, a 
young bearded Russian physician stood up and said in broken English “this is all very 
interesting, but we have no access to such drugs in Russia, so how can we apply such 
approaches?” This made the main conclusion of my talk somewhat futile and required 
me to address the issue with a whole different clinical regimen based around the 
resources they did posses, namely; good old hands on bedside skills and strong 
physiological knowledge, something that has been lost to some degree in the western 
world with our reliance on technology and drugs. I leant a number of valuable lessons 
that day; one being the importance of researching and adapting your material to the 
audience, another the disparity in healthcare services from one country to another, and 
most importantly the need to ethically develop medical devices that can be utilized as 
broadly as possible in the less developed countries. Ethics is critical not only in day to 
day business dealings, but equally so in our approach to address the enormous 
healthcare problems we face and will be vital if we are to overcome the great economic 
and access to care divides that exist globally (Schor, et al., 2011).I will explore this 
concept of healthcare business ethics further in chapter 4 that details my public works 
related to the innovations that I have implemented.  
 
To broaden my formal educational background, which to this point had all been in 
engineering, I decided to undertake a management qualification and attended evening 
classes to complete my postgraduate Diploma in Management Studies. This decision 
was driven by my desire to further work my way up the corporate ladder and an interest 
to broaden my scope of expertise into other areas within the medical device field. 
However, I recall being concerned at the time about breaking through the ‘Glass 
                                                            
2 Hemodynamic regulation is critically important when trying to mange an acute lung injury patient in acute 
respiratory distress syndrome with a lung protective ventilator regimen. (J. Zhang, 2011) 
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Ceiling’, related to my trade school working-class background. Probably more precisely 
referred to as the “old boys’ network as expounded on at the time by Jones and Lewis 
(1998) and that was clearly still in play in British society. Although the company I worked 
for was American and you would believe was less affected by such stereotypes, there 
was certainly a pecking order for promotions and career advancement within the British 
led arm of the organization. Therefore, to progress and succeed, I felt I would need to 
broaden my horizons. My proposition at the time was simple and twofold; 1) that there 
would be greater opportunities and hopefully rewards outside of the purely engineering 
and educational arenas where I had spent the earlier part of my career, and 2) that I had 
to take full advantage of the unique Anglo-American organization3 for which I worked. 
This premise came true in short order, in that both my academic and professional 
achievements were recognized as I was offered a position as an Education Department 
Manager based out of the company’s newly completed factory in Southern California, 
USA.   
 
2.2. Expanding my horizons and continued workplace learning 
 
Moving continents was a milestone moment in my career. I would go as far as to say it 
might be the most important decision I ever made and required me to reflect on not just 
what I wanted to do, but also on who I wanted to be. From what I had seen and 
experienced, America was clearly the land of opportunity, less encumbered by the 
historical restraints that existed within British industry and founded out of adversity for 
freedom of choice and the right to self-determination. This was a country that I felt 
championed innovation and cheered for the underdog, where you are applauded for 
trying and not castigated for failing. Here I hoped I could take my proud British heritage 
and utilize the knowledge and skills I had learnt to further progress up the career ladder. 
Once in California I took on responsibility for a broader education department. I 
spearheaded the development of a number of new training programs and oversaw and 
participated in the provisions of over thirty week long educational classes each year. I 
also took advantage of the company’s supportive continuing education policy and soon 
had attended the two week residential professional sales training program by the 
National Society of Sales Training Executives (NSSTE) which today is known as the 
Professional Society for Sales & Marketing Training (2012). This course was unique as it 
was a train the trainer program voluntarily taught by leading sales and marketing 
training executives from some of the world’s leading companies (Procter and Gamble, 
Wachovia and IBM etc.) and focused on the skills of teaching and developing training 
                                                            
3 Technically probably more accurately referred to as an American-Anglo organization as it was an American parent 
company. 
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material and presentations.  By this time that I had come to appreciate that my life did 
not just happen and that I was responsible as to how it might manifest over time. I also 
realized that as part of my self-development and acquisition of skills, that it was equally 
important that I honed my time management, effectiveness and ethical awareness 
capabilities. To this end I attended the Seven Habits of Highly Effective Leadership 
weeklong seminar in Utah, hosted by the eminent Stephen R Covey himself. This course 
taught me not only new skills but introduced me to many concepts that to this day I 
utilize in daily practice. The structured idea of independence (self-mastery and being 
true to oneself) combined with interdependence (working together synergistically and 
ethically towards a win-win) and the awareness of the importance of continued 
rejuvenation of these principles, is beautiful in its straightforwardness and incredibly 
relevant in today's increasingly complex business environment (Covey, 1989). Dr. Covey 
explains it best in discussing his sequel, The 8th Habit - From Effectiveness To Greatness 
(2004), by saying “In today's challenging and complex world, being highly effective is the 
price of entry to the playing field. To thrive, innovate, excel, and lead in this new reality, 
we must reach beyond effectiveness toward fulfilment, contribution, and greatness.” 
(Covey, 2012). In forthcoming chapters I will elaborate on how I believe I have become 
more effective in the implementation of innovation within my area of expertise and 
have attempted to live up to these lofty ideals of fulfilment, contribution, and greatness.  
 
Being based now out of the factory that was responsible for the development and 
manufacture of all of the company’s intensive care ventilators, I was provided with the 
unique opportunity to immerse myself in many new facets of the business. I believe that 
work-based learning can be osmotic as well as through structured programs, a concept 
characterized by Reinsmith (1997, p. 1) as being a process of unconscious immersion in 
one's immediate environment. In this manner I was able to absorb new knowledge from 
my daily discussions with a multitude of colleagues. I attended numerous one-on-one 
and team meetings with engineers and scientists to discuss the intricacies and function 
of many new medical devices, which spanned the gamut of intensive care and 
respiratory segments, as the company was involved in pushing the barriers that had 
existed previously between such diverse specialties. One project I recall involved a 
revolutionary continuous fibre-optic intra-arterial blood gas analyzer, that additional to 
the technological challenges, posed new questions about how to interpret and utilize 
this previously unavailable real-time data to best affect patient care. More information 
is not always a good thing if you cannot interpret it in context. In order to gather 
comparative data from patients with different acute conditions, I spent a number of 
weeks between the operating theatres and intensive care units of Stanford University 
Hospital in San Francisco. The new knowledge gained by this project supported the 
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evolution of new visual models that when published allowed for a graphical shape 
representation of all the variables in such a way that an “average” clinician might be 
able to utilize them to impact treatment regimen for their patients. (Adam seiver, 1993) 
This was literally an eye-opening experience that cemented my interest and desire to 
explore further the clinical aspects of my chosen field.  
 
By this time my career path had moved away from that of the dedicated educator and 
became increasingly more interested in the marketing and business aspects of my 
chosen field. I decided that the next step should be to migrate into product marketing 
management where I would have direct influence on what products would be 
developed, how they would be developed and on the sales and marketing strategy to 
introduce them into the marketplace. Here I spearheaded the development of a number 
of new products, fostering them through Research and Development (R&D), regulatory 
approval, into production and then orchestrating their release into the marketplace. By 
the very nature of these medical device products, I believed it was imperative to 
broaden my knowledge base to include the perspective of the clinical user. I therefore 
decided to take evening classes again and enrolled into a clinical degree program in 
respiratory care, which involved a significant hands-on clinical practicum component. 
Having worked in the field for over a decade at this time I had a strong understanding of 
the physiological and technological aspects of respiratory care. However, it was an eye-
opener for me having to spend approximately two thousand hours working as a 
respiratory therapist student at numerous local hospitals. This provided me the 
opportunity to put myself in someone else's 4 shoes, which is a phrase commonly used 
to refer to a way of gaining empathic Intelligence (Sherman, 2009), and in this case 
allowed me to appreciate their perspective. Only by doing this could I truly understand 
how our life support ventilators directly impact the lives of the patient and caregiver. I 
found out from clinicians what features and aspects of our devices were liked and 
gained many insights into improvements we could make. On completing this program I 
became credentialed as a Certified Respiratory Therapist5 by the National Board for 
Respiratory Care (2012). I had also cemented my career move by this time and was 
initially the Product Marketing Manager, then Senior Product Marketing Manager and 
ultimately the Group Product Marketing Manager for the organization, with a full 
department below me. Throughout these positions the knowledge I had gained through 
formal and informal means across varying areas of specialization was put to work on 
numerous work projects. From directing my daily practice, to influencing my 
                                                            
4 the clinician’s 
5 A Respiratory Therapist is a licensed healthcare provider that focuses on the treatment of respiratory problems 
and the management of ventilator support for such patients, similar to a respiratory nurse specialist in Europe. 
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interactions with others, to steering new product development and the product 
development road map, to conducing marketing surveys, to developing sales and 
marketing materials and programs for our sales executive, and for end user clinicians, to 
conducting sales and clinical education seminars, to authoring trade related 
publications. Two specific early example of an educational public work product that had 
direct impact on the community, and as such are examples of my public works are the 
Technical (Griffiths, 1996) and Clinical (Griffiths, 1996) Handbooks of Metabolic 
Monitoring6. These publications were made available as educational booklets to any 
interested parties by the company at no charge and allowed interested academics, and 
clinicians in the respiratory care field, to educate themselves on the science and 
importance of non-invasive metabolic monitoring of critically ill patients. An area where 
traditional predictive equation methods and approaches were shown to be inaccurate, 
resulting in inadequate nutritional support and exacerbated ventilator consequence 
(Faisy, et al., 2003). The new knowledge imparted here was of the very highest 
academic level and covered complex clinical and technological subjects, helping to bring 
a clear and precise learning to many different professions involved in dealing with these 
issues in ventilated patients. These publications were an early introduction for me into 
the rigors of academic research in an involved subject. I learnt extensively how to apply 
a good methodological approach to these studies and enhanced my ability to provide 
critical review and analysis of complex subjects.  The culmination of this was clear and 
concise publications that address informatively new knowledge and explain a new state-
of-the-art technology. Over a decade later, the knowledge imparted by these booklets is 
still valid and unique in that no other real-time integrated metabolic monitoring product 
for ventilated patients has been developed and these metabolic monitoring devices are 
still in use in numerous institutions throughout the globe; (Reid, 2007) (Faisy, et al., 
2003), (Miwa, et al., 2003).etc. These newly learnt abilities and this work result clearly 
helped me to further my career and formed the basis for my approach to many projects 
that ultimately helped me to progress further up the corporate ladder within the 
                                                            
6 Metabolic monitoring traditionally refers to a spot-check measurement of a patient’s Oxygen Consumption (VO2) 
and Carbon Dioxide production (VCO2)production, which when divided by each other gives you the Respiratory 
Quotient (RQ) and can be used to calculate the total Resting Energy Expenditure (REE), which is a measurement of 
total caloric needs. The problem was these measurement were inherently difficult to obtain and the values taken 
on a spot check basis did not track true metabolism as the patient’s clinical condition varied over time, resulting 
commonly in dangerous overfeeding, underfeeding and inadequate ventilator support. The unique technology 
outlined in these booklets provided easy real-time continuous measurements of these previously described 
parameters, and along with that with an entered urine urea value (representing nitrogen metabolism))the actual 
breakdown of substrate (Fat, Protein and Carbohydrate) metabolism for the patient.  This provided unheralded 
accuracy in the adjustment of the nutritional support of the ventilated patient in terms of total caloric needs and 
substrate mix, as well as appropriate ventilator settings management. 
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corporation. 
 
During this time I really “grew-up” in the ways of the industry and started to realize that 
maybe there were better ways to do things that were not so encumbered by larger 
organizational structures and NIH7 syndrome. I started to think that maybe innovative 
excellence could be achieved if there was less focus on the process and more on the 
outcomes and customers? This concept was aptly illustrated by Abrahamson & 
Freedman (2008, p. 181) when they pointed out that “Instead of trying to figure out the 
best way to do something and sticking to it, just try out an approach and keep fixing it”. I 
would say that at this time my entrepreneurial wings had started to unfold. Despite my 
clear frustrations, I stuck with it and attempted to change the culture from within. I 
continued to move upwards within the organization and ultimately ended up at the 
divisional group management level. During this period I gained extensive knowledge and 
participated in the leadership of the division, utilizing many of the skills I had acquired in 
planning, organization and not least communication throughout the business unit. For 
every new project, I had overall responsibility to research the market opportunity, 
assess the development costs and timelines, conduct financial Return On Investment 
(ROI) analysis and ultimately argue whether, or not, to move forward with the project. 
Once the project commenced, my department then had oversight of the R&D and 
regulatory submissions and then planned transition into manufacturing and the whole 
global release to sales, including developing all the marketing material and campaigns. 
Finally though, as the company was to be acquired for the third time, this time by the ill 
fated TYCO conglomerate that was then led by the now convicted Dennis Kozlowski 
(Ackman, 2005). I grew disillusioned with continually justifying my existence in an ever 
changing organization that seemed to lack focus and even more so direction. The time 
had come for me to leave my comfort zone and see if I could fly.  
 
  
                                                            
7 NIH = Not Invented Here 
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2.3. Spreading my entrepreneurial wings 
 
My first start-up venture was called eVent Medical Ltd., which was a company based on 
unique technology and a ventilator patent that I had jointly filed and was consequently 
issued (Griffiths & Daescher, 2006) that allowed for a ventilator to be controlled and 
monitored remotely utilizing a mini-web server over a Local Area Network (LAN).  This 
was a revolutionary new approach and I was able to form the company around this core 
Intellectual Property (IP) and raise investment from Angel type friends and family 
investors to develop the ventilator and bring it to market as was highlighted in a 
periodical at the time (Lytle, 2005). This was a period of great change and learning for 
me, as I had to transition from the corporate world to the start-up world. One of the 
greatest challenges for me during this time was navigating the world of start-up finance, 
as after the initial angel round of investment, we needed to raise an additional 
investment and the financial markets became significantly tougher during this period.  
 
Despite all the new challenges I faced being the Chief Executive Officer (CEO) and 
founder of my own company, this period was one of the most liberating in my career, as 
I was able to do things how I felt they could best be done. Not to say that I was always 
right, but with the formation of a strong team of professionals and innovative global 
quasi virtual infrastructure8, we were able to quickly show what could be done with 
focus, Completing development, testing, regulatory approvals and releasing out first 
intensive care ventilator, aptly named the “Inspiration” to sales in less than 2 years. This 
product also followed the ethical approach discussed earlier and provided extensive 
high-end features at a price point that was affordable in most markets around the globe. 
We continued to grow the company and released various further products for 6 years 
until the company was sold to a multi-billion dollar Japanese conglomerate, Kobyashi 
Corporation (2007), This transaction not only resulted in positive financial outcomes for 
all the investors and vested employees, but also allowed for a much larger company to 
continue the legacy we had started and bring our product into the hands of an even 
greater number of clinicians around the globe. Calculated from my own eVent Medical 
Ltd. sales numbers and the annual reports of Kobayashi corporation (2010), on average, 
about four hundred Inspiration family ventilators have been sold each year, looking at 
the last nine years of sales and utilizing a 50% utilization rate and a conservative 
Ventilator Length of Stay within the Intensive Care Unit (ICU) estimate (T. Williams, 
2008), this would equate to well over 150,000 patients that have been treated 
                                                            
8 By quasi-virtual infrastructure I mean that the company had employees based at many different locations (many 
cases their home offices) around the globe and we communicated daily via internet, online conference calls and 
email etc., not that it was an cyberspace (internet) company only as the term commonly refers. 
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worldwide with one of my Inspiration family of ventilators.  
 
Next I moved on from the respiratory and ventilator field into the wound care field with 
the formation of my current enterprise, Advanced Oxygen therapy Inc. This company is 
focused on developing and marketing Topical Oxygen therapy that incorporates another 
of my patented technologies (Griffiths, et al., 2009) that utilizes Oxygen in a topical 
application to heal previously non-healing wounds, including; Diabetic ulcers, pressure 
ulcers (bed sores), other chronic and acute wounds. This new entity required me taking 
my strong methodological approach and researching a completely different clinical 
specialty. Even though challenging, I found the process fascinating and have quickly 
become a subject matter expert in topical oxygen for wound care, having spoken at 
numerous conferences around the world (Griffiths, 2012). I heavily relied on my 
experience with my first start-up in establishing the structure for this new venture and a 
number of my former employees were happy to come along and join me in something 
new. Additional to the many common challenges discussed before, this opportunity has 
provided new challenges as our technology allows for easy patient treatment in the 
homecare environment where reimbursement is required for a therapy to be successful. 
The Centres for Medicare & Medicaid Services, Office of the Actuary, National Health 
Statistics Group (2011, p. 2) estimates that Home healthcare expenses in the USA 
totalled approximately $110 billion in 2010 and accounted for an astonishing 1% of GDP. 
So the opportunity is enormous, as are the potential healthcare system benefits, as it is 
commonly accepted to be a far cheaper site of care than institutional alternatives. This 
being said, the bar for gaining reimbursement has been steadily raised over the years 
and in most major markets around the world the regulators require clear clinical 
outcome improvements over alternative treatment options, which involves costly 
Randomized Controlled Clinical Trials (RCT). Conducting the research to develop these 
trial protocols and then drafting them with the physician investigators has provided a 
new area of learning for me that has resulted in publication of the protocols and 
resultant trial outputs (clinicaltrials.gov, 2012). Additionally, as this business has grown 
and further investment funds were required to fund the clinical trials etc., I have had to 
develop various detailed business plans, investment schedules and complex financial 
models to present the opportunity to a varied broad selection of potential investment 
partners, which range from private equity funds, venture capitalists and traditional 
bankers. A process that has become progressively more difficult and taken up 
increasingly more of my time, since the global financial market meltdown in 2008 and 
access to funds have been significantly reduced. This is evidences by the National 
Venture Capital Association (2011) that estimates that there was a 54 percent Drop-off 
in venture industry fundraising from 2008 to 2010. 
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2.4. Subject matter expertise  
 
Throughout my years in Product Management and then as entrepreneur, I continued to 
further my learning and love of teaching. The actual manner in which I taught migrated 
away from weeklong classes and more towards shorter conference presentations and 
half day seminars. This was driven somewhat by my changing role to that of an 
entrepreneurial executive, but also by my increased recognition as a subject matter 
expert. In the words of one great American president and visionary, Abraham Lincoln; “I 
don’t think much of a man who is not wiser today than he was yesterday” (1809-1865) 
an ideal I have certainly tried to embrace. I have travelled extensively around the globe 
on speaking and business engagements, having presented at numerous congresses and 
symposia worldwide on a wide range of topics as detailed in my CV (Griffiths, 2012). The 
length and level of each presentation varies dependent on the content matter and the 
audience, but generally the lectures were between 1 hr – 3 hrs in duration. In most 
cases the audiences were business professionals, healthcare executives, clinicians or 
physicians in the medical device field. These presentations commonly required the 
introduction of new ideas, or approaches, that were then contrasted to existing 
evidence. In a number of cases this would have fostered new ways of thinking and direct 
new knowledge. These presentations were made available to all attendees of the 
conferences as handouts or in abstract books and were unrestricted for onward general 
public circulation (Griffiths, 1995 - 2012). The public impact of these presentations 
varies dependent on the content, material and audience. For example, at the 2010 
Caribbean Healthcare Congress in the Cayman Island, which was attended by regional 
health ministers and professionals, I brought awareness to the Chronic Wound epidemic 
caused by obesity and diabetes. Introducing many startling facts about the impact on 
the quality of life and healthcare economics to that region, is today I hope positively 
influencing healthcare policy in the region (Griffiths, 2010). I cherish the thrill of 
presenting to a new audience and interacting with them in open dialogue. The skills I 
have established over the last 26 years provide me with the professional ability of a 
public speaker, that when combined with the knowledge I have been successful in 
absorbing, provides me the credibility as a product matter expert in my field of 
expertise. I expect to continue to learn and teach in some manner until I die.  
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3. Barriers To Successful Implementation of Innovation Within the 
Non-Invasive Medical Device Field 
 
Merriam-Websters dictionary defines Innovation as “1: the introduction of something 
new; 2: a new idea, method, or device” (2012) and it is believed to have originated from 
the Latin in the mid 1500s9.  Clearly this term can be, and has been, used to describe the 
introduction of new ideas, products or concepts in every sphere of human influence 
ranging from the social sciences to engineering (Godin, 2008). Another term that is also 
used in combination and originates from the same period is that of Inventor, which 
Rossman in his book entitled ‘The Psychology of the Inventor’ (1931) simply defines as 
one who “creates or introduces something new” (p. 25). In Denny and Dunham’s 
excellent book on the subject titled ‘The Innovator's Way’ they explain that innovation 
and invention are related but different insomuch that the practice of invention is related 
to the early stage of overcoming a problem, or creating an opportunity, whereas the 
practice of innovation is related to taking the offering provided by the invention through 
the adoption stage into the community (2010, p. 8). Especially in case of medical device 
technology there is no shortage of inventors that come up with innovative new 
products, or approaches to a problem, that never make it into the marketplace due to 
their inability to overcome any number of the barriers to entry. Marketplace 
implementation of such innovations is then critical, I believe, in order for the innovation 
to be deemed a success as it does no good for mankind to leave it on the shelf to gather 
dust. 
 
My analysis and discussion that follows will focus on the specific barriers that need to be 
overcome in taking an innovative idea that has been developed into an early stage 
product and implementing it successfully into the marketplace within the non-invasive 
medical device field10, from the perspective of the practitioner, which in this case is the 
innovator and implementer. I will not be looking at the inventive stage itself, but more 
at how to take an innovation forward from this stage to successful marketplace 
implementation. I will illustrate the process by citing examples from my own public 
works of how I addressed and overcame these barriers with a couple of specific 
innovations. I will not focus on the operational and financial challenges of running and 
                                                            
9 Not surprisingly this being the middle of the Renaissance period and scientific revolution when the likes of 
arguably the greatest “Innovator” ever, Leonardo da Vinci, were in their heyday. (Lemelson-MIT Program 2004) 
10 Medical devices can be split into two main categories; “Non-Invasive” meaning they do not go within the body 
and “Invasive” meaning they go into the body. The regulatory pathway for Invasive product is somewhat similar to 
that of Drugs and is distinctly different to that of non-invasive devices. I focus on the later as this being my area of 
expertise. 
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funding the business, but will defer that to the next chapter, where I will thoroughly 
detail my distinct contributions and their impact in the field. 
 
In the table that follows, I have outlined the general barriers that every medical device 
innovator must overcome when looking to implement their innovation. This is not 
meant to be an exhaustive list but a general outline of the most significant factors and I 
will then elaborate further on each key component as they relate to my public works 
experience and professional practice. 
 
Medical Device Barriers to Innovation Implementation 
 Barrier Challenge 
a. Achieving and maintaining an 
adequate Quality System 
The initial barrier to entry is that you 
must comply with any array of 
quality system requirements 
throughout the world  
b. Transferring the design from 
prototype phase to 
manufacturing 
Innovating in the laboratory is only 
one step. Making sure the design is 
manufacturable is more difficult. 
c. Gaining regulatory clearances 
for the device  
There are distinct regulatory 
clearance channels and processes 
that must be followed within the 
USA, European Union, Japan and 
most countries worldwide in order 
to market a device legally. 
d. Establishing distribution 
channels 
With regulatory clearances in hand 
you now need to establish your 
route to market. 
e. Gaining reimbursement for the 
device  
Regulatory clearances are the 
“Ticket to Play”. Reimbursement is 
often required to make any money 
from the endeavour. 
 
3.1. Achieving and maintaining an adequate quality system 
 
The concept of quality systems evolved out of the Industrial Revolution in the 18th 
century, which resulted in an outpouring and sustainability of inventions (Smith & et. al, 
2004). The resultant exponential growth in technology and towards mass production, 
and away from individual skilled craftsman that built an item from start to finish, 
necessitated that quality be overseen by someone in order for it be consistently 
maintained. This concept morphed further over time and was tailored by quality control 
professionals to every type of manufacturing and industry. It’s surprising that although 
20 
 
manufacturers would internally follow quality control processes, that formal quality 
systems in the medical device field did not become mandatory until the 1980s, despite 
being in place for drug manufacturers at least a decade before. Throughout the 
following three decades these quality system regulations went through various changes 
and consolidations, including migrating from individual country specific standards to 
more harmonized regional standards, something that was significantly achieved by the 
formation of the European Union.11 In general quality systems comprise the simple 
elements of saying what you will do, doing it as you said you would and documenting 
that you actually did it. 
 
You cannot market a medical device within the USA, European Union or pretty much 
anywhere else in the world unless you achieve and maintain compliance with the 
appropriate quality system standards. For many people this task can be overwhelming 
as the depth of the standards seems on first glance to be excessive. However, with a 
systematic and pragmatic approach, compliance can be achieved. This involves 
developing procedures and documentation for all aspects of the business and 
implementing these procedures on a daily basis.  In my first start-up enterprise, eVent 
Medical Ltd., I personally took on the task12 of attaining compliance to these standards 
and recall vividly how much work was involved in drafting all the procedures and 
required forms and documents. I would spend countless late nights trying to apply the 
regulations to my specific new venture and innovative ventilator products that we were 
developing, such that the procedures were not just there on paper, but were actually 
effective in their purpose for our small company. This is evidenced within my public 
works quality system manual (Griffiths, 2001). I strongly believe that ethically, you 
cannot just pay “lip service” to quality systems by one time developing a “cookie cutter” 
quality manual with all the procedures neatly aligned per the standards, as this is a 
recipe for disaster. You need to work within the framework of the regulations and adapt 
the procedures to suit your very specific business needs and continuously re-assess and 
make changes to them, as your business is not a static entity and the quality system 
should evolve as it does. As detailed by the Global Harmonization Task Force (Rotter, 
2008) report, this concept of active implementation is also becoming an area that 
regulators are paying more attention to in the quality surveillance audits as well. 
 
As Burr points out in his report titled “Quality System Development in Medical Device 
                                                            
11 For most of the initial decades, these standards were  the protected domain of a country’s official standards 
organization, for instance British Standards in the United Kingdom, to develop and regulate the rules, something 
that was difficult for them to give up for harmonization’s sake, until mandated due to the European Union 
formation. 
12 I took on this task out of necessity as the company originally only had 2 employees. 
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Start-ups” (Burr, 2004) the Quality Systems themselves, although there are some minor 
differences, primarily address the aspects of designing, manufacturing and marketing of 
medical devices. They tend to be broken down into the general categories of Design 
Controls, Production and Process Controls, and Post-market surveillance.    
 
The two main regulations that have solidified in the last decade are; 
 
3.1.1. International standards organization (ISO) 13485:2003 medical devices - 
quality management systems  
  
This is an evolutionary standard13 that has been adopted by the European Union 
and the majority of countries outside of the USA. Compliance to this standard is 
the minimum required to manufacture products to market in these countries, 
along with certain country specific additions. Unlike the USA requirement 
discussed below, attainment and compliance to this ISO standard is achieved by 
annual physical audits of the company by a duly authorized entity, which are 
referred to as a notified body. These notified bodies can be either government 
standards organizations, such as BSI in the United Kingdom or TUV in Germany, 
or private certification companies, such as SGS and MedCert etc. 
 
For the innovator, it is not only important to develop the documentation and 
systems to comply with Quality Management System standard, but they also 
have to decide the most appropriate notified body to contract with. It’s clear 
that although these bodies are required to audit to the same regulations, there is 
room for individual interpretation and approaches. This raises potential ethical 
dilemmas for the innovator, as on one hand you might want to utilize the most 
thorough notified body in order that your quality system is assessed as 
effectively as possible, but on the other you don’t want to be subjected to audits 
and interpretations of the regulations that are overly punitive and raise too 
many unnecessary corrective actions. Another consideration is that of cost, as by 
effectively opening up this function to an open-market approach, you have all 
these notified bodies competing for your business. I have struggled with this 
issue in both of my start-up entities, having used both private and governmental 
bodies in each. My decision process was based on such factors as the nature of 
my products to the entity’s expertise, the manufacturing site location relative to 
the body and of course the cost consideration. The problem is that even though 
                                                            
13 Evolutionary in the sense that the standard is updated occasionally and when a new version is released the year 
of that release is included in the title of the standard itself, hence ISO 13485:2003 is the current active release. 
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you can freely change from one notified body to another, it’s easier said than 
done as it also impacts your product’s regulatory approval for CE mark and this is 
a much more complex and time consuming issue as you will see later on. 
 
It’s also become painfully evident that some are clearly more vigilant than 
others, as is expertly pointed out by Stewart Eisenhart (2012)in his article in 
Mass Device   that discusses the obvious oversight shortcomings by the notified 
body in the case of the French breast implant manufacturer, Poly Implant 
Prothèse, resulting in the European Health and Consumer Policy Commissioner, 
John Dalli, demanding tighter vigilance and the notified body verification 
 
3.1.2. US Food and Drug Administration: 21 CFR 820 quality system 
regulations 
 
The regulatory oversight for medical devices in the USA is conducted by the Food 
and Drug Administration (FDA), a federal government agency within the U.S. 
Department of Health and Human Services.14  The FDA requires most medical 
devices to be developed under design controls and within a quality system.15 
Unlike the ISO standards discussed above, the FDA does not proactively audit 
medical device manufacturers of non-invasive devices for compliance to these 
regulations; instead the manufacturer is required by law to state their 
compliance and maintain current registration of the company and cleared 
devices within the FDA databases.  So here the onus is put onto the 
manufacturer to be compliant.  
 
The FDA does however execute random audits of medical device companies, 
which can be conducted by any of the local or regional offices. Historically, lower 
risk, non-invasive medical device manufacturers were unlikely to be audited 
unless their devices had been involved in a corrective action or recall. This 
resulted in what many people believe to be a dichotomy of oversight, which was 
even further exasperated internationally by the lack of international audit 
resources within the FDA, meaning foreign manufacturers were even less likely 
to be paid a visit by an FDA inspector. It also meant that as an innovator you 
would fear an FDA audit as it was usually preceded by a problem. To help 
alleviate this perception and help manufacturers prepare for an audit the FDA 
                                                            
14 Per the FDA website (2012) the agency employs over 11,500 personnel. 
15 Dependent on whether the device is classified as Class 1 - 3 dictates the level of quality system requirement. The 
higher the risk the device the greater the depth the quality system needs to cover. 
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established guidelines for inspections of foreign medical device manufacturers 
(FDA, 2010). More recently the FDA has also announced it has stepped up its 
auditing and inspections of foreign companies (HealthDay News, 2011). I can 
personally attest to this trend having had my Irish based company audited by the 
FDA in 2011 without any preceding incident. 
 
Even though there has been a lot of focus over the last ten years on trying to 
harmonize worldwide quality standards into one regulation, a Global 
Harmonization Task Force was formed in 1992 that includes members from all 
the major regulatory bodies around the globe and this task force has issued 
numerous recommendations and talking papers (Rotter, 2008), but to date has 
been unsuccessful in moving much closer to a global harmonized quality 
standard. In large part due to the nature of the regulations, that is enshrined into 
the laws of each individual country, but also due the vested interests of the 
various competent authorities in the different jurisdictions around the globe. 
That being said, I believe strongly that these efforts need to continue as anything 
that can be done to standardize and simplify the global framework for medical 
device manufacturers and help innovators navigate the current convoluted web 
of regulations, would go a long way to improve compliance and efficiencies. Not 
to mention the potential cost saving benefits that would come out of 
streamlining this enormous barrier to innovation implementation. This is an area 
that I advocate during my speaking engagements and by my membership of 
various industry associations, such as the Medical Device Manufacturers 
Association etc as detailed in my CV (Griffiths, 2012). 
 
3.2. Transferring the design from prototype phase to manufacturing 
 
The process of design and technology transfer into manufacturing is commonly 
underestimated by inventors as their focus tends to be on the inventive step itself. The 
attention to detail and skills required to achieve manufacturing success has resulted in 
the establishment of specific design transfer and manufacturing engineering specialties. 
Khandani states that “Engineering is the creative process of turning abstract ideas into 
physical representations” (2005, p. 4), so by this premise, design transfer and 
manufacturing engineers take the physical representations that the inventor has 
evolved out of abstract ideas and makes them into something that can be reproduced. 
In other words, these experts take innovations and complete the metamorphosis from 
prototype to a manufacturable product and do so while maintaining compliance with 
the required quality system and regulatory standards detailed in other sections. In most 
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cases these engineers are also responsible for developing adequate procedures and 
documentation to cover the processes involved in a controlled and verifiable manner. 
So the importance of inventing and designing medical products with manufacturability 
as a key concept at the earliest stage should not be underestimated, otherwise you may 
end up with a great invention that is impractical to make and effectively useless to the 
real world. To coin a phrase from Dr. Covey’s second habit of highly effective people; 
“Begin with the End in Mind” (Covey, 1989).16 In the next chapter I detail my 
contribution in this area with a number of my public works that demonstrate the 
importance of this concept and were thereby implemented more effectively into the 
marketplace. 
 
3.3. Gaining regulatory clearances worldwide 
 
Like with the Quality System certification process discussed previously.  There are two 
predominant regulatory clearances required to market a non-invasive medical device 
worldwide. These are the US FDA 510(k) and European Union CE mark. With these 
clearances obtained you are able to market your product within the USA and European 
Union, and you can utilize this to gain similar status in the majority of other countries, 
with Japan being an exception as it has its own dedicated process called Shonin. For the 
innovator, navigating the myriad regulations and gaining these approvals is daunting, 
but is a requirement if you want to legally market your device. It is evident as detailed in 
the table below that the primary focus for most medical device companies are the USA 
and European Union marketplaces, as combined they account for close to $200 billion in 
annual sales and approximately 80% of the worldwide medical device market (Espicom, 
2011). However, like with other goods, the importance of the Asian and South America 
countries is growing as their economic development and resultant spending on 
healthcare continues to increase. 
 
                Figure 1.  Worldwide Medical Markets Forecast to 2016 from ESPICOM (2011) 
                                                            
16 It is interesting how many parallels can be drawn between the business and life skills ideals  
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I will focus on these two main regulatory clearances in more detail below, but again the 
harmonization of regulatory pathways, would like with quality system pathways 
discussed previously, have huge potential benefits if the powers to be would allow it to 
happen. 
 
3.3.1. European Union CE mark: medical devices directive (93/42/EC) 
 
The medical device directive outlines the rules and approach needed to assess 
what category (or class) a device falls into. From this the required regulatory 
hurdles are determined. There are four classes for medical devices, progressing 
from 1, 2a, 2b and 3 and with class 1 being devices posing least risk and class 3 
the most. As you would imagine the approval pathway is more involved in 
devices of higher risk then in ones with less perceived risk.17 The majority of non-
invasive medical devices fall into class 2a and 2b and there are a couple of 
different approaches (annexes) that a company can take to gain approval based 
upon their structure, quality system status and expertise.  For both these classes, 
the innovator must develop what is referred to as a “technical file” and submit 
this for approval to their notified body. The technical file contains a declaration 
of conformity and classification assessment, all the design specifications and 
verification tests results, details of adherence to the essential requirements of 
the directive including any specified standards for the type of device, a detailed 
risk analysis and a clinical assessment. Unless the device is of a completely new 
nature, there are no requirements to conduct clinical trials, as long as you 
conduct a detailed clinical literature review and address any questions of safety 
in the risk analysis. As you can see the onus for the approval is on the company 
and the actual approval is given by the notified body as a conformance of the 
product to the directive within the quality system framework. This approval is 
limited to usually three years and is then assessed again at that expiration, 
primarily for adherence to changes in the regulations and for updated risk 
analysis. Once this certification has been achieved, you can apply the CE mark to 
your product and it can be freely marketed within the EU18. It is also important 
to point out that the product approval is only valid as long as your quality system 
                                                            
17 This is also mirrored in the Quality system requirements, where higher classification devices require more 
stringent oversight and control processes. 
18 The CE mark for devices of class 2 or higher include a  number that designates the notified body, for instance our 
CE mark for our wound oxygen therapy system is CE 0050, with 0050 being the National Standards Authority of 
Ireland’s duly designated Notified Body identification number, for the purposes of the European Communities 
(Medical Devices) Regulations (S.I. No. 252 of 1994)  
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is in compliance and this is assessed annually.  
 
3.3.2.  US FDA 510(k) per 21 CFR 807.92(a)(3). 
 
In the USA medical devices are classified as either class 1, 2 or 3, with devices 
posing most risk in the higher category. Most devices that are class 2 and some 
that are class 1 require the submission of what is called a 510 (k) Premarket 
Notification. The FDA refers to this approach as risk based oversight and its 
various components are shown in the graph below (Pate & Watson, 2011). 
 
 
                           Figure 2. Risk based Oversight from Food and Drug Administration  
                         Overview of Medical Device Regulation (2011) 
 
Similarly to the CE mark, a 510(k) is a formal premarket submission packet made 
to the appropriate centre within the FDA. Most commonly for non-invasive 
devices this will be the Centre for Devices & Radiological Health (CDRH). 
However, instead of showing conformance to certain essential requirement 
regulations, in this case the purpose is to demonstrate that the device to be 
marketed is “substantially equivalent” to a legally marketed predicate device.  
Demonstration of substantial equivalence fundamentally means that the new 
device is at least as safe and effective as the predicate, in such that; it has the 
same intended use; and has the same technological characteristics as the 
predicate. It is acceptable for the device to have same intended use as the 
predicate but with different technological characteristics, as long as this does not 
in the opinion of the reviewer raise new questions of safety and effectiveness. So 
a claim of substantial equivalence does not mean the new and predicate devices 
27 
 
must be identical. Substantial equivalence is established with respect to 
intended use, design, energy used or delivered, materials, chemical composition, 
manufacturing process, performance, safety, effectiveness, labelling, 
biocompatibility, standards, and other characteristics, as applicable (U.S. 
Department Of Health And Human Services, 2010). So if this can be established 
with adequate detail and supporting test data etc. to the reviewer’s discretion, 
then they will issue a premarket notification letter and you are cleared to legally 
market the device within the USA. 
 
As was pointed out by an eminent Committee on the Public Health Effectiveness 
of the FDA 510(k) Clearance Process (2011) in a report on the topic; like with the 
CE mark, for lower risk classification devices, no clinical trials are required to gain 
US marketing clearance.  This is a topic that has recently created some 
controversy in the general public as to whether medical devices should be 
cleared through the 510(k) process without the need for on patient clinical data. 
This issue was stirred up by awareness that a number of hip implants that failed 
and required removal had been cleared to market through this route (Meier, 
2011). There is always a balancing act between having adequate opposed to 
burdensome regulations, which normally always comes down to a risk to benefit 
analysis.  This topic raises a number of ethical considerations. Clinical trials are 
incredibly expenses and many products would simply never make it to market 
and be allowed to help needy patients. Of course this has to be tempered with 
the premise that we do not ever want to do harm to a patient. But I am not sure 
that clinical trials necessarily provide a guarantee of no harm, as there are many 
drug products recalled (Celebrex and Viox come to mind recently) from the 
market after terribly harmful side effects were discovered, that had all gone 
through extensive phase trials for safety and efficacy  prior to being approved.   
 
It is my opinion, and that of all the industry trade groups such as ADVAMED 
(Advamed, 2012) in the USA and EUCOMED (Eucomed, 2012) in Europe, that 
requiring lower risk devices to have in-vivo19 clinical data as part of their 
regulatory submissions would be enormously damaging to the entire healthcare 
system and would stifle innovation. No premarket regulatory system for medical 
devices can guarantee that all new medical devices will be completely safe and 
effective when they reach the market. This view is also supported by the 
                                                            
19 In-Vivo refers to within the body or on patient  
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eminent committee that was formed by the Institute of Medicine20 to study The 
Public Health Effectiveness of the FDA 510(k) Clearance Process (2011) and 
which concluded that “No premarket regulatory system for medical devices can 
guarantee that all new medical devices will be completely safe and effective 
when they reach the market. Robust post-marketing surveillance is essential”. 
The committee also went on to state that the “current 510(k) process was 
flawed based on its legislative foundation” and should effectively be scrapped 
allowing the FDA to better allocate its resources towards a new framework that 
would better address safety and effectiveness across the device’s life cycle. The 
FDA firmly rebuked this idea. 
 
As I described earlier, in my first start-up I personally managed and completed all 
the regulatory and quality requirements for the business. An example of this 
from my public works is my submission for and resultant approval of the 510(k) 
marketing clearances for the Inspiration21 Ventilator ( Food and Drug 
Administration, 2002), this submission summary are openly available to the 
public via the FDA website (FOOD AND DRUG ADMINISTRATION, 2012) and with 
a request for information, the entire submission can be provided to any 
interested party. This public domain documentation availability is invaluable I 
believe as part of the ongoing sharing of knowledge within the field and by its 
very nature imparts new learning. This information is also helpful in making sure 
that companies conduct their advertising and promotional activities ethically and 
only market their products for their approved intended-use. Sweet and 
colleagues (2011) looked at this issue in detail and concluded that misbranding 
or mislabelling of medical devices, be it unintentionally or by design, is a problem 
that is becoming only too common within the industry. The following chart 
succinctly summarises the main differences in the Quality systems and 
Regulatory requirements between the two transatlantic continents: 
                                                            
20 The Institute of Medicine serves as adviser to the nation to improve health. Established in 1970 under the 
charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-
based advice to policy makers, health professionals, the private sector, and the public 
21 A registered trademark of eVent Medical Inc. 
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   Figure 3. Quality systems and Regulatory requirements between the two transatlantic continents: (Cittadine, 2010) 
3.4. Establishing distribution channels 
 
It is critical that once you have the medical device ready to ship and the regulatory 
clearances to market it, that you establish appropriate and effective distribution 
channels. In general marketing terms this encompasses at least one of the founding four 
Ps22, namely; Place, a concept first proposed by the eminent E. Jerome McCarthy (1960). 
This barrier to success should not be underestimated as many products have failed to 
meet expectations due to an inadequately thought out strategy. Distribution may be 
established in many different ways dependent on the type of product and resources 
available to the company. In most cases it is necessary for an innovator to partner with 
experienced regional or national medical device dealers or distributors, especially in 
foreign markets. This allows for a multiplication of resources and a focus on the relative 
areas of expertise of each party. It is reasonable that over time and as the business 
grows that the distribution approach should be adjusted and in many cases will evolve 
at a point of critical mass in the core home markets into a direct organization. I will 
elaborate further on this barrier and cite examples from my own experiences in the next 
chapter. 
 
3.5. Gaining reimbursement for the device 
 
With the aforementioned barriers being addressed it is time to start taking-on possibly 
the biggest obstacle to success; reimbursement. That is not to say this should be left to 
the end, on the contrary it should be paramount as part of your business strategy. There 
is no universal model to how medical devices are paid for or reimbursed; instead each 
country has its own approach.  
                                                            
22 Price, Product, Promotion and Place 
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There are also major demographic trends that are shaping the healthcare 
reimbursement landscape in its entirety. The increasing proportion of elderly population 
caused by the baby boom after the last world war and much improved life expectancies, 
combined with skyrocketing per capita healthcare spending costs and the rise in chronic 
debilitating and expensive diseases, such as Diabetes, Obesity, Asthma and COPD,23 are 
all creating a perfect storm of spiralling healthcare costs that will sink our global 
economies if not addressed by the policymakers.  The U.S. Centres for Medicare and 
Medicaid Services, Office of the Actuary, "National Health Statistics Group” (2012) 
estimates that healthcare expenditures exceeded two and a half trillion dollars in 2010, 
with 45% of this massive amount being paid for by government programs such as 
Medicare and Medicaid, 40% by private insurance, and the remainder out of the pockets 
of the patients directly.  
 
It also depends on the nature of the medical device as to whether reimbursement is a 
direct or indirect concern for the innovator. By this I mean that if the product is an 
expensive piece of capital equipment targeted for hospital use, then specific 
reimbursement is not usually required to be able to go-to-market as these types of 
products are usually amortized under a hospital’s capital budget and not charged back 
to a payer on a fee-for-service24 basis, but instead bundled into a prospective or 
capitated payment for treating a particular condition etc. So for these products the sales 
strategy hinges around a traditional competitive price and feature set to convince the 
purchaser to chose your product over an alternative. Conversely, products that are 
targeted into the homecare or physician’s office environment are commonly charged 
back to the payer on a per-use or utilized specific fee-for-service basis. In these cases, 
until you have reimbursement established you have no sales at all.  
 
3.5.1. Reimbursement in the USA 
 
There are several organizations within the USA that are involved in establishing 
reimbursement rates for reimbursed medical devices. The primary entity is the 
Centre for Medicare and Medicaid Services (CMS). This agency was formed in 
1965 and today administers both the Medicaid (program for the poor and 
disabled) and Medicare (senior citizens over 65) programs that combined 
account for the majority of all US health expenditures and close to 800 Billion 
dollars, or 24%, of the entire Federal budget in 2010 according to the Medicare 
                                                            
23 Chronic Obstructive Pulmonary Disease (COPD )such as emphysema and bronchiolitis  from smoking and 
pollution. 
24 Fee for service relates to the approach of charging for a specific item or procedure once utilized 
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Spending and Financing Primer published by the Kaiser Foundation (2011). By 
default anything that is covered by CMS is also covered by the Private insurance 
companies as they effectively let the agency act as the gate keeper.  
 
The process of gaining CMS Reimbursement requires that you petition at the 
national or one of the four regional levels for a coverage determination. The 
coverage and analyst group within CMS then initiates a process as detailed in the 
table below. The primary assessment criteria are simply sufficient confidence 
exists that the product or service “improves health outcomes generalisable to 
the Medicare or Medicaid population” (2012). To reach these conclusions the 
agency utilizes a strict evidence based medicine approach25. Therefore, it is 
virtually impossible to get reimbursed for a new medical device without at least 
one well thought out Randomized Controlled Clinical Trial26 that shows a positive 
outcome over an existing treatment regime.  Due to the complexity of ethics 
committee approval and the high per patient trial costs in the USA, there is a 
clear trend to conduct clinical trials in less burdensome and less costly regions, 
such as Europe, especially in the eastern European Community member states 
like Poland, and also in India. 
 
 
Figure 4. CMS Coverage Determination Process, CMS Website (2012) 
                                                            
25 Evidence based medicine relates to making clinical decisions based on the outcome evidence from controlled 
clinical trials and not on gut feeling or personal conjecture.  
26 By well thought out I mean that it should have appropriate clear primary outcomes that are proven with 
sufficient weight to be deemed statistically significant 
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So even though clinical trial data is not required for regulatory approval, you can 
see that it is critical for reimbursement if that is a factor for success with a 
particular device. Because it is prohibitively expensive to conduct these trials 
until the device has regulatory approval, most companies commence them at 
that stage, resulting in a common time gap of two to three years from release to 
sales of a device before being able to get reimbursed. This is an issue that is very 
difficult for small companies to manage and stay financially viable, especially 
when you consider that a small 100 patient randomized clinical trial may cost 
upwards of $1 million to conduct.  
 
One of my public works examples that illustrate this area is the protocol and 
study manual for a clinical trial developed in 2008 for our unique Topical Wound 
Oxygen device for use on diabetic ulcers (Griffiths, 2009). The process of drafting 
this manual and developing all the associated documents; tracking forms and 
study manual for the investigators etc., required months of intensive research 
into not only expectations of the reviewing agencies,27 but also into the diabetic 
ulcer clinical field included extensive review of other trials in the same field . It 
also involved a certain amount of statistical analysis to calculate adequate 
sample sizes based on likely outcomes etc. Like all clinical trials conducted in the 
USA, the protocols have to be published online in the US governments 
clinicaltrials.gov (National Institute of Health, 2012) database and are publicly 
accessible to anyone who wishes to view them. This project was significant to me 
in that I was able to master new skill and gain new knowledge in that area. 
 
There are some unique government agencies, such as the Veterans 
Administration, where medical devices are procured from the Federal Supply 
Schedule (FSS). A distinctly separate process is followed to get listed on the FSS 
and awarded a 5 year contract, which involves extensive product comparison 
and utilization data, but does not require clinical trials to prove outcome. In the 
case of the Topical Wound Oxygen product line discussed previously, I was 
successful in the process and my company was awarded a 5 year contract that 
allowed for fair reimbursement of our devices on both a direct purchase and 
rental basis. (DEPARTMENT OF VETERANS AFFAIRS, 2009). Like many start-up 
companies this target market segment has provided the company with adequate 
repeat business to survive and grow while investing in the larger clinical trials 
needed for broader coverage. 
                                                            
27 I use the term agencies  as I developed this protocol to meet the requirements of not just the USA CMS agency 
but also that of various European reimbursement bodies as well 
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3.5.2. Reimbursement in Europe and internationally as a whole 
 
In Europe and especially within the European Union countries, each country 
manages their own healthcare expenditures and system. Most of the countries 
are dominated by a socialized medicine approach be it centrally funded like the 
iconic National Health Service (NHS) in the United Kingdom, or funded by 
government but administered via private insurers like in Germany.  Universally 
though the same evidenced based medicine approach is used to grant 
reimbursement for devices, in that you require at least one well thought out 
Randomized Controlled Clinical Trial that shows a positive outcome over an 
existing treatment regime. The UK National Institute for Health and Clinical 
Excellence (NICE28) is a prime example of how the European agencies have also 
been including health economic data in their decision process, as it takes a 
relatively inflexible and formalistic approach to health technology assessment 
that is based on the concept of the cost per quality-adjusted life year. (Castle & 
Kelly, 2010) 
 
The difference is that many of the reimbursement decision makers are 
increasingly expecting to see some of the in-vivo data collected on patients 
within their borders, making the design of the clinical trial plan even more 
difficult for a start-up company, as they now need to consider utilizing multi-
centred and multi-national studies when gathering their outcome evidence, or 
potentially face being forced to repeat these costly trials.  
 
Outside of the European Community there are various reimbursement structures 
that are either predominately government funded or a mix of low end 
government funded care with high end private care for those that can afford to 
pay. In any case, if the need for reimbursement exists in any of the countries the 
same challenges and approaches outlined previously would need to be adopted 
on a country specific basis by the innovator. One exception to this structure is 
Saudi Arabia and the Arabian Gulf region as a whole, where due to its extensive 
current wealth and ballooning healthcare service need, there is a net result of a 
five-fold estimated growth rate in total health-care spending in the region by 
2025 when it will reach US$60 billion (Mourshed, et al., 2011). As the region is 
investing enormously in healthcare and is predominantly a direct purchaser of 
equipment without requiring any kind of reimbursement, but just the award of a 
tender for the goods, this opens up simpler opportunities for new devices. 
                                                            
28 An unfortunate acronym for an agency that has a reputation for saying NO to reimbursement requests 
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A general trend that is being seen globally in many countries around the world 
that are all experiencing the same skyrocketing costs of health care, is that many 
are addressing this issue by such draconian approaches as simply reducing 
reimbursement rates or establishing price caps, without much logical thought for 
the impact to the caregivers and device manufacturers. This knee jerk approach 
although somewhat effective initially does nothing to get at the root of the 
problems and penalizes in many cases those that rely on the care most, whilst 
waste and misappropriations continue elsewhere.  
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4. My Contributions to Implementing Innovation More Effectively 
Within the Highly Regulated Non-Invasive Medical Device Field  
 
4.1. Defining Innovation Implementation 
 
Over forty years ago Myers and Marquis (1969) concluded that; “Innovation is not a 
single action but a total process of interrelated sub processes. It is not just the 
conception of a new idea, nor the invention of a new device, nor the development of a 
new market. The process is all these things acting in an integrated fashion” (Trott, 2005, 
p. 15)29. From my review of the literature on implementing innovation contained in 
appendix 1 it is evident that in order for innovations to be successful, especially as they 
are related to new technological products, they (the innovations) must be developed 
through an organizational process that is managed such that the more individualized 
entrepreneurial R&D efforts are aligned appropriately with the business’s strategic 
leadership, goals and the various important market drivers (France, et al., 2011). 
Managing the innovation process through all the stages and spheres of influence while 
taking on the inherent risks is really what entrepreneurship is all about. France et al go 
on to say that the “development and implementation of ideas that create value (is) the 
essence of effective innovation” (2011, p. 52). This definition is notable in that it 
introduces the importance of value creation in assessing if an innovation is actuality 
effective.  Despite this clear underlying theme in the literature, Tidd (2006) points out 
that there still seems to be some disparity, especially between the organizational and 
product/technological fields, as to exactly what is meant by the ‘Implementation of 
Innovation’.  Predominantly throughout the newer models of innovation, 
‘Implementation’ is proposed as the final stage of the process, that follows both the 
Innovative stage (design, development and production), and the Adoptance stage 
(market release and initial use) (Austen & Martin, 2002), (Godin, 2008). However, the 
term is also used to refer to the entire process of taking an innovation (idea) through its 
earliest deployment stages, through market release, and then into its long term 
utilization (Jessup-Ange, 2009). Whatever definition you use, it is clear that ending the 
innovative process at the adoptive phase will result in failure. This is particularly evident 
for technological innovations. Peslak et al (2007) go to great lengths to emphasize this in 
their detailed review of the literature, which showed that up to 30% of technological 
innovations never get implemented despite being initially adopted.  
                                                            
29 MYERS, S.; MARQUIS, D.G.; Successful industrial innovation: a study of factors underlying innovation in selected 
firms, National Science Foundation, NSF 69-17, Washington DC 1969 quoted in TROTT, P.: Innovation Management 
and New Product Development, 3rd edi-tion, Prentice Hall, Harlow 2005, page 15 
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Many researchers, including; Christensen et al. (2004), have concluded that small 
companies tend to be the most innovative and commonly provide an organizational 
environment that is more conducive to innovation. Tidd and Besant (2004) emphasize 
the importance of developing an organizational culture that facilitates radical 
innovation, opposed to just incremental innovation. Berkun in his book, The Myths of 
Innovation (2010), states poignantly that innovation results from good knowledge that is 
based on lived experiences, further supporting the notion that there must always be a 
practical real world component for the idea to truly be innovative. 
 
In their paper looking at the inherent tensions that exist between Innovation and its 
Implementation, Austen and Marten state it well when they say “organizations that 
foster creativity, visionary leadership, fast-cycle learning, and flexibility should respond 
effectively to the pressures of today’s innovation-driven marketplace” (2002, p. 8). This 
paper goes on further to implore that innovation alone is not enough and should be 
accepted as a prerequisite, and that effective adoptance and implementation are key to 
a business’s success. More recently, Muna Kalyan (2011) explains that innovative 
organizations are by their very nature organized to take on risks and manage constant 
change. He elaborates that distinctively such organizations “puts knowledge to work on 
products, processes, technologies, and markets, and eventually on knowledge itself.” 
(2011, p. 84). The literature consistently supports the concept that the key to achieving 
this in an organization requires an environment conducive to innovation and that 
incorporates four facets; culture, organizational structure, people and technology 
(Fiates, et al., 2010). Consequently, Druker’s (1985) adages still hold true when he 
simply summates that innovation implementation and entrepreneurship are all 
unequivocally linked. 
 
To assess the validity of my claim, we need to first define what is meant by 
Implementation of Innovation relative to my specialized field of expertise, namely; the 
non-invasive medical device field. Based on the brief discussion above and my review of 
the general literature on the subject contained in Appendix 1, I believe that in this case 
the implementation of innovation should best be considered in its broader technological 
context, that being; the complete process of developing an Innovation by overcoming all 
of the varied barriers (development, regulatory, finance, marketing and business etc.) to 
successfully implement it into the marketplace, which is consistent with the definitions 
by the likes of; Rhodes and Wield (2000), Austen and Marten (2002), Klein and Knight 
(2005) and Singhal and Dearing (2006) to name a few. Effective implementation can 
then be thought of as achieving appropriate committed use of the innovation by a 
primary target user as Klein et al. (2005) (1996) so aptly espoused. I think this definition 
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is most appropriate as it provides a direct measure of real market (user and clinical) 
effectiveness of the innovation and the process that brought it to market within a 
specialized field.  
4.2. More effective implementation of innovation from my public works  
 
In the remainder of this chapter I will explore my public works and related evidence, 
with focus on how they support my claim of making a unique contribution that has had 
significant impact within my field of expertise, and specifically will show that I have 
implemented a number of innovations more effectively within the highly regulated non-
invasive medical device field. I will also further elaborate on how I have predominantly 
achieved my claim by establishing and managing small innovative and uniquely 
structured enterprises along the lines of those depicted by Christensen et al. (2004), 
which by their very nature epitomize entrepreneurship. Utilizing the definition of 
effective implementation established in the opening section of this chapter and 
analyzing my claim in its entirety, I believe it is useful to break the analysis down into 
distinct component parts, which can then be reflected on individually as they relate to 
my claim for the innovation in question. 
 
A critical element of an effective implementation process is identifying innovations that 
address proven needs, a concept strongly supported by France et al (2011) with their 
insistence on the importance of value creation from innovations. Therefore, I have 
started my analysis here and once this prerequisite has been established, I will expand 
the discussion to address the effectiveness of their implementation. Following on from 
this we need to define what is meant by the term ‘more effectively’ in my claim. Simply 
put, effectively can best be defined as the implemented innovation producing the 
decided, decisive, or desired effect, which is commonly referred to as synonymous with 
the term ‘efficiency’ (Merriam-Websters, 2012). The European Commission in its report 
on Making public support for innovation in the EU more effective, offers up a definition 
of innovation efficiency as; that which “aims at ensuring maximum results with limited 
resources” (2009, p. 31) and then goes on further to differentiate this from innovation 
effectiveness, that they define as; “delivering what is needed on the basis of clear 
objectives, an evaluation of future impact and, where available, of past experience” 
(2009, p. 31). So to ultimately understand whether these innovations were 
implemented ‘more effectively’ than commonly seen within the non-invasive medical 
device field, we will need to compare them against the industry timelines, costs and to 
other user and clinical norms for such measures.  
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In the following sections I have detailed three specific innovations of mine from as 
examples from my broader public works. As an introduction, the following bullet points 
provide an executive summary of each of these innovations as they relate to my claim 
and as to whether the innovations were implemented more effectively than is normal 
within the field, these are then discussed in greater detail following this summary. 
 
4.2.1 Executive summary 
 
Were the specified Innovations Implemented more effectively than is normal in the 
field? 
 
Public Works Example 1:  Topical Wound Oxygen Therapy System and AOTI Inc. 
  
Organization and product implementation effectiveness 
 
 Assessment criteria: 
 Reduced time and cost to implement the innovations into the marketplace than 
 is normal within the field. 
 
 How was this achieved: 
 Established and managed innovative diversified quasi-virtual company that 
 implemented the products quicker and for less cost than is normal.  
 
 How is this evidenced: 
 - Innovative company structure evidenced by my strategic business plan for the 
 company (Griffiths, 2011) and company website (AOTI Inc., 2012) and by 
 Distribution partner testimonials (USA and International Distributors, 2012). 
 - Innovation was implemented within the global marketplace in less than half of 
 the normal average 4 to 5 years timeframe (Kaplan, et al., 2004), (Combs, 2009), 
  (Cittadine, 2010) and for a total capital investment in my company of less than 
 $5 million as shown in my strategic business plan  (Griffiths, 2011, p. 14), that is 
 between 25% and 50% of the cost that is normal within the industry 
 (Makower, et al., 2010), (Cittadine, 2010), (Shah, 2012), (Espicom, 2012). 
 
Regulatory and reimbursement implementation effectiveness 
 
 Assessment criteria: 
 Achieving required regulatory approvals and reimbursement faster and for 
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 lower cost than is normal within the field. 
 
 How was this achieved: 
 Competency focused approach and innovative company structure resulted in 
 USA and European regulatory approvals and USA reimbursement being achieved 
 faster and for lower cost than is normal. 
 
 How is this evidenced: 
 - Faster regulatory approvals and timelines evidenced by regulatory approval 
 notifications; EU (National Standards Authority of Ireland, 2007) and in the USA 
 (Food and Drug Administartion, 2008). 
 - Faster reimbursement and timeline evidenced by Department of Veterans 
 affairs  contract award (DEPARTMENT OF VETERANS AFFAIRS, 2009). 
 - Achieved in less than the low end of the normal two years and for no additional 
 cost as evidenced by the my strategic business plan for the company  
 (Griffiths, 2011), compared to the normal $2 million to $3 million for each major 
 region sought (Espicom, 2012), (Makower, et al., 2010), (Kaplan, et al., 2004). 
 - International Congress success press release (Doyle, 2010). 
 
Clinical outcomes and healthcare cost saving implementation effectiveness 
 
 Assessment criteria: 
 The impact of the implemented product on healing wounds and reducing direct 
 and indirect healthcare costs relative to other products in the field  
 
 How was this achieved: 
 Implemented innovation provides direct cost and healthcare system savings by 
 healing wounds completely and more effectively with less reoccurrence in a 
 lower cost homecare setting. 
 
 How is this evidenced: 
 - Wound healing effectiveness evidenced in multiple clinical publications and 
 alternate therapy comparisons as evidenced by, (Sultan & Tawfick, 2010),  
  (Derk, 2011), (Blackman, et al., 2010) etc., as well as in numerous clinician 
 testimonials (Frykberg, et al., 2012). 
 - The published extensive clinical trial protocol (Griffiths, 2009). 
 - Cost savings evidenced by extrapolated Quality Adjusted Life Years (QALY) for 
 the therapy of $2,475, compared to the cost per QALY of other alternate 
 therapeutic modalities; $27,310 for Full Body HBO (Chow, et al., 2008), €24 881 
 for Negative Pressure Wound Therapy (Whitehead, et al., 2011) 
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Ethical implementation effectiveness 
 
 Assessment criteria: 
 Global implementation of a clinically significant treatment modality so that as 
 many patients as possible can benefit. 
 
 How was this achieved: 
 By the resultant global clinical use of the innovation and the education of the 
 community as to the scope of the problem and best treatment options. 
 
 How is this evidenced: 
 - Global clinical utilization evidenced by the growing and varied number of 
 clinical  papers; (Adler & Frye, 2012), (Blackman, et al., 2010),  
 (Frykberg, et al., 2012), (Sultan & Tawfick, 2010) etc. 
 - Over 1,000 patients have been successfully treated in the USA alone. This is 
 calculated from the prescription orders for the therapy within the USA and 
 number of treatments, and the duration of therapy provided. Approximately 
 twice this amount has been treated globally. This is supported by the figures in 
 my strategic business plan. (Griffiths, 2011, p. 4). 
 - My presentations at conferences globally over the last five years as detailed in 
 my CV and conference presentations (Griffiths, 2012). 
 
Public Works Example 2:  Inspiration Ventilator Product Family and eVent Medical   
 
Organization and product implementation effectiveness 
 
 Assessment criteria: 
 Reduced time and cost to implement the innovation into the marketplace than 
 is normal within the field. 
 
 How was this achieved: 
 Established and managed non-traditional diversified quasi-virtual company 
 structure that implemented Inspiration ventilator family into the market in less 
 time and for far less cost than is normal. 
 
 How is this evidenced: 
 - Innovative company structure evidenced by my strategic business plan for the 
 company (Griffiths, 2005) and local newspaper article (Lytle, 2005). 
 - Inspiration Ventilator implemented within the global marketplace in three 
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 years and for a total capital investment of only 3 million dollars. This is less than 
 the normal 4 to 5 years a timeframe (Cittadine, 2010) (Combs, 2009) and 
 between 15% and 30% of the cost that is normal within the industry, 
 (Kaplan, et al., 2004), (Makower, et al., 2010). (Cittadine, 2010), (Shah, 2012),  
 and is supported by my strategic business plan and model for the company  
 (Griffiths, 2005). 
 
Clinical outcomes and healthcare cost saving implementation effectiveness 
 
 Assessment criteria: 
 The impact of the Inspiration product on providing clinical availability reducing 
 direct and indirect healthcare costs relative to other products in the field. 
 
 How was this achieved: 
 Implemented innovation provides direct cost and healthcare system savings by 
 providing high end clinical features in a more flexible low cost design making the 
 device more economically viable for less developed markets and countries. 
 
 How is this evidenced: 
 - The Inspiration offers significant high-end performance capabilities at a price 
 point of far lesser performing products as evidenced within my eVent Medical 
 Strategic Plan (Griffiths, 2005, p. 24). 
 - Viability for less developed markets demonstrated within the eVent Medical 
 Strategic Plan by the sales mix of products being distributed throughout the 
 globe with many sales into the lesser developed markets.  
 - The Inspiration’s Heliox and NIV feature can help wean patients off the 
 ventilator quicker (Flynn, et al., 2010), (Venkataraman, 2006).Per patient 
 ventilator days costs an incremental $1,522 (Dasta, et al., 2005), extrapolating 
 these savings out shows that the Inspiration acquisition price could be offset 
 entirely by just six patient ventilation days saved. 
 
Public Works Example 3: The 7250 Metabolic Monitor Project 
 
 Assessment criteria: 
 The 7250 innovation provided significant clinical impact and was implemented 
 within  a shorter time then normal despite inconsistent resources allocation. 
 
 How was this achieved: 
 I managed a small focused team that developed the product and all 
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 ancillary educational materials, and released it into the marketplace. 
 
 How is this evidenced: 
 - Clinical impact is evidenced by the innovations continued utilization across a 
 widening gamut of conditions, as demonstrated in numerous clinical papers 
 citing its use over the last decade; (Reid, 2007) (Faisy, et al., 2003),  
 (Miwa, et al., 2003). (Brandi, et al., 1999), (Barco, et al., 1998). 
 - The Clinical (Griffiths, 1996) and Technical (Griffiths, 1996) metabolic 
 monitoring handbooks provide evidence of the clinical benefits and materials 
 developed. 
 -The 7250 was implemented in the marketplace in less than  four years and for a 
 minimal amount of capital expense allocation from the corporation, which is less 
 than normally seen in field (Makower, et al., 2010), (Cittadine, 2010). 
 
I will now elaborate in detail on each of the innovations summarized above, including 
identifying the innovation developed, the global health need addressed, and my 
associated public works in which it is evidenced. I will further explain and examine each 
of these innovations to assess its impact specifically as it relates to; the global health 
need that they purport to address, the details of the innovation that addresses such 
need, and the effectiveness of its implementation. Finally, I will answer the key question 
to my claim of whether the innovation was implemented more effectively than is 
normal in my field of expertise. 
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 4.2.2. Topical Wound Oxygen Therapy (TWO2 )
30 System and AOTI Inc.  
 
Innovation Global Health Need 
Addressed 
Evidenced within/by  
Public Work 
Topical Wound 
Oxygen Therapy 
(TWO2 )  System 
 
AOTI Inc. 
Company 
Non-healing Chronic (Diabetic, 
Pressure or Venous related) 
ulcers and acute wounds 
  
TWO2  Patent (Griffiths, et al., 
2009) 
 
TWO2  Clinical Trial Protocol 
(Griffiths, 2009) 
 
AOTI Inc. Business Plan and 
Models (Griffiths, 2011) 
 
TWO2  Product Datasheets 
(Griffiths, et al., 2012)  
 
AOTI Inc. Website (Griffiths, et 
al., 2012) 
 
 4.2.2.1. What is the global health need? 
 
This innovation can be utilized clinically on a broad array of chronic and acute conditions as 
evidenced by the range of wounds treated, the resultant papers published in peer reviewed 
journals and those presented at the various international medical conferences, including those 
of the; European Wound Management Association and USA Vascular Surgeons (Blackman, et al., 
2010), (Sultan & Tawfick, 2010), (Kivelä, 2010), (Adler & Frye, 2010), (Derk, 2011), (Kuspelo & 
Veikšina, 2011), (Adler & Frye, 2012). However, due to the enormity of the problem and lack of 
effective alternate therapeutic options, non-healing chronic (diabetic, pressure or venous) ulcers 
remain the innovation’s core focus, as they represent the largest global health need within the 
wound care segment, afflicting as much as 3% of the global population (Nerac, Inc, 2007), 
resulting in a direct healthcare cost associated purely with their management
31
 of over $55 
billion annually (Medtech Insight, 2009). Current technologies and other therapeutic approaches 
do not address chronic wounds adequately and provide on average wound healing rates no 
better than 30%. (Medtech Insight, 2009). As much as 25% of all diabetic patients have chronic 
recalcitrant
32
 ulcers (Whitehead, et al., 2011) and many ultimately lose limbs to amputation or 
even their lives to the resultant infections (IDF Diabetes Atlas, 2011). For diabetic ulcers alone, 
these associated costs
33
 account for between 15% and 25% of the total healthcare resources 
                                                            
30 Topical Wound Oxygen and TWO2 are Trademarks of AOTI Inc. 
31 By management I mean treating and maintaining the ulcer but in the majority of cases not necessarily healing it  
32 Non-responding, Reoccurring, Non-healing 
33 Costs associated with; treating the wound, amputating the limb, post amputation care, prosthetics etc. 
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spent on diabetes as a whole ((WHO), 2005), or as much as $116 billion annually (IDF Diabetes 
Atlas, 2011).  
 
 4.2.2.2. What is the Innovation that addresses this need? 
 
Appropriate Innovation identification is a critical element of an effective 
implementation process and the National Science Foundation in the United States 
points out the impact of research can be increased by moving the innovation to realistic 
deployment, linking new knowledge to economic growth and other societal benefits 
(Plimpton, 2012). This concept of understanding the customer’s or segment’s needs fully 
before embarking on developing an innovation has been extensively researched with 
the most effective innovators being shown to have created stronger ideas in the front 
end of the process, based on truly understanding their target segment’s needs (Ross, 
2009). The importance of developing Innovations that address real, opposed to 
perceived, needs, is paramount in my opinion, when assessing its impact in the field, but 
also its effectiveness.  
 
To help address this enormous health need34 and provide patients with an alternate, 
and most importantly, more effective, therapeutic option, I formed a new company, 
AOTI Inc., (Griffiths, 2011) with the intent to develop and ultimately patent the Topical 
Wound Oxygen innovation (Griffiths, et al., 2009). Invention patents are a finite work 
product that by their very patentability have gone through extensive peer review and 
are made openly available to the public via the USPTO website (United States Patent 
and Trademark Office, 2012).The resultant unique TWO2 therapy product innovation 
addresses this global health need with simple to use devices that can be applied by the 
patient at home without the need for costly clinical caregivers. (Orsted, et al., 2012) The 
therapy has been shown to provide greater than 80% complete healing of these 
previously non-healing chronic ulcers with virtually no reoccurrences of the ulcers for up 
to three years. (Derk, 2011) (Sultan & Tawfick, 2010) (Blackman, et al., 2010). These 
resultant work products include the formation of new knowledge and an innovative 
technology as detailed in the product patent, clinical trial design, the products 
themselves and in the company structure that was put in place to implement them. 
 
                                                            
34 Enormous in terms of both the clinical consequences/costs  associated with them and also their epidemically 
growing prevalence worldwide 
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 4.2.2.3. Was the innovation implemented effectively?  
 
I drafted, submitted and achieved the required USA Food and Drug Administration (FDA) 
marketing clearance, the  application and authorization being publicly available via FDA 
510k website (FOOD AND DRUG ADMINISTRATION, 2012). The effective completion of 
product development and transfer of the innovation into manufacturing and release to 
sales is evidenced by the product datasheets (Griffiths, et al., 2012) and the company 
website. (Griffiths, et al., 2012). Successful Adoptance35 of the innovation is also 
evidenced by this and the company’s initial sales performance for the product detailed 
in the business plan utilized by the various stakeholders (Griffiths, 2011). The 
Innovation’s adoptance is further demonstrated by the successful reimbursement for 
the therapy and the award of a federal contract within key US market segments, such as 
the Veterans Administration (VA) and other federal segments etc. (DEPARTMENT OF 
VETERANS AFFAIRS, 2009). 
 
The clinical trial protocol that I drafted (Griffiths, 2009) demonstrates the innovation 
was not only developed and the required global regulatory approvals were achieved, 
such that an in-vivo randomized controlled patient trial could be conducted in order to 
provide evidence of greater efficacy for broader reimbursement, but also of successful 
implementation of the innovation36, as feedback from the clinicians and users after 
initial adoptance of the innovation helped me define the desired treatment protocols 
and the primary and secondary end points for the trial. The trial protocol itself was peer 
reviewed by experts within the field and by a number of institutional review boards, was 
then published and made available to the public via USA Federal Government public 
access clinical trial website (clinicaltrials.gov, 2012).  
 
Successful implementation and meaningful impact of the innovation is further 
demonstrated by the ever growing product sales shown in the business and strategic 
plan (Griffiths, 2011, p. 55) and expanding clinical utilization within the global healthcare 
community as evidenced by the ever growing number of clinical publications on an ever 
broader range of wound related clinical conditions, including such conditions as ; 
takayasu’s arthritis (Kuspelo & Veikšina, 2011), venous stasis ulcers (Adler & Frye, 2012) 
(Sultan & Tawfick, 2010), septic forefoot Phlegmone (Adler & Frye, 2010), diabetic ulcers 
(Derk, 2011) (Blackman, et al., 2010), pressure ulcers (Kivelä, 2010) , complex 
                                                            
35 Adoptance being the initial market use and acceptance.   
36 Klein and Knight (2005) define the difference between Adoption and Implementation as the former being that of 
the “decision to use an innovation” and contrastingly the later being ‘‘the transition period during which 
[individuals] ideally become increasingly skilful, consistent, and committed in their use of an innovation.” 
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recalcitrant wounds in multi-morbid patients (Japour, et al., 2012) (Levine, 2011), to 
name a few. Another measurement of an innovative medical product’s effective 
implementation within an intended market segment, as well as its acceptance within 
the clinical community as a whole, is that when the innovation is utilized into standard 
treatment regimes, that clinical evidence based practice guidelines and standards are 
developed by experts in the field, and such is the case with the recently published; 
‘Evidence-based practice standards for the use of topical pressurized oxygen therapy 
(TWO2 )’ (Orsted, et al., 2012). 
 
The combination of the meaningfully improved clinical outcomes, the growing list of 
clinical indications, combined with the direct clinician and other stakeholder feedback, 
have also resulted in further product enhancements and product line extensions as 
detailed in the strategic plan (Griffiths, 2011) that epitomizes successful innovation 
implementation along the lines defined by Klein and Sorra (2005) and (1996), who 
describe Implementation as a process of achieving appropriate committed use of the 
Innovation by a primary target user and go on to further state that “It is the critical 
gateway between the decision to adopt an innovation and its routine use” (1996, p. 
1057). 
 
 4.2.2.4. Was the innovation implemented more effectively than is normal 
   within the field?  
 4.2.2.4.1. Organizational and product implementation effectiveness 
 
As mentioned in the introduction to this chapter, to address the question of whether 
these implemented innovations were implemented more effectively then commonly 
seen within the non-invasive medical device field, we will need to compare them against 
both industry norms and alternate treatment options. As discussed, in order to develop 
and bring this innovation to adoption and ultimately for it to be implemented fully 
within the wound care market, I had to establish a new company, AOTI Inc. utilizing the 
skills that I had learnt as an entrepreneur in forming and running my previous start-up 
entity eVent Medical Ltd. as summarized in my CV (Griffiths, 2012) and that will be 
discussed in more detail in the next section. In structuring this new company, I put in 
place a diversified and quasi-virtual organizational structure that by its very nature 
fostered innovation along the lines described by Malhotra in his book; Knowledge 
Management and Virtual Organizations (2000). As this author points out, just the 
creation and implementation of such an organizational structure and culture can be 
considered implementing innovation alone. Rather than building redundant and costly 
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departments to accomplish all the needed functions of the organization and to 
overcome the numerous barriers to entry outlined in the previous chapter, my approach 
was to bring on board a focused team of proven experts in the core competencies 
needed to be successful, and then outsource/contract-out the necessary ancillary 
support functions as detailed in my strategic plan for the company (Griffiths, 2011). This 
resulted in a truly global business that has cross-linked functions that utilize all the 
modern day communication tools available and an interactive management approach. I 
was able to hire the best candidates for their respective functions regardless of 
geographic location. This is evidenced by fact that our core business functions; R&D, 
Manufacturing, Regulatory & Quality, Sales, Marketing and Clinical Affairs, are managed 
by employees based in seven different countries and detailed on our website (AOTI Inc., 
2012). The benefit of this decentralized model has been that that the company has 
attracted and retained some of the industry’s best talent, allowing it to be very nimble 
and to react more effectively to the challenges encountered when fostering the 
innovation towards successful implementation37. The very nature of this business 
structure and approach has provided numerous efficiencies in all the business functions 
mentioned above, which is supported by the testimonials of numerous USA and 
International distribution and channel partners (USA and International Distributors, 
2012). The ultimate result of which has been the successful global marketplace 
implementation of the Topical Wound Oxygen Therapy product line in less time and at 
far less cost than is normal within the industry.  
 
In assessing this claim of effectiveness further, we need to first understand what are 
normal implementation times and costs within the non-invasive medical device field. In 
his presentation on Medical Device Development, Cittadine provides a good review of 
this area and explains that the commercialization timeline from early product 
development through regulatory approval is commonly 4 to 5 years and for small 
companies usually involves multiple rounds of financing totalling $10 million - $20 
million (2010), and this does not include the time or cost required to achieve 
reimbursement in any significant market sector or geography. In the case of AOTI Inc., I 
was able to finance the company and the resultant Topical Wound Oxygen Therapy 
innovation development, including complete market release and initial reimbursement, 
solely through what is referred to as ‘friends-and-family’38 financing, and one Angel 
                                                            
37 Core role driven and decentralized business models are imperative for success in the downturned economy we 
are faced with in which greater efficiency and effectiveness are key themes (Pigorini, et al., 2011) 
38 Friends and family refers to raising money intrinsically from the business proprietors and immediate associated 
parties.  
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investor39 round. The total capital investment in the company to date is less than $5 
million, $2 million of which came from one individual angel investor (Griffiths, 2011, p. 
14). This funding approach was driven somewhat by the desire of the principles to 
maintain as much ownership of the company as possible, but primarily by the lack of 
any acceptable Institutional funding40.  
 
The importance of having achieved this implementation effectiveness with AOTI Inc. and 
having effectively done more with less is only amplified by the lack of small medical 
device company capitalization options available since the global financial market 
meltdown in 2008. In the last four years, the  availability of capital within the medical 
device sector has swung 180 degrees, with less than 30% being made available now to 
smaller companies,41 which is the complete opposite of conditions in 2007 (Ernst & 
Young, Global Life Science Center, 2011). Simply put, you have to already have money to 
be able to borrow or recapitalize within the sector. Ernst & Young’s annual report on the 
state of the medical technology industry (2011) further elaborates on the incredibly 
difficult landscape that companies have faced in the last four years, which they describe 
as the “new normal”, characterized by a radically changing; reimbursement, payment 
and regulatory environment, coupled with a significantly more challenging financing 
climate, that has all added up to put “Innovation at risk” (2011, p. 2). It can be 
summarised that the financial crisis not only dried up access to traditional capital routes 
for start-up companies within the industry, but has had profound impact on the ability 
of any medical device that is developed to get reimbursed and ultimately paid for by the 
healthcare systems that are in many cases being subjected to freefall austerity 
programmes.  
Having successfully structured and funded an innovative company, AOTI Inc., which 
developed and implemented the Topical Wound Oxygen Therapy innovation within the 
global marketplace in less than half of the normal 4 to 5 years a timeframe (Kaplan, et 
al., 2004), (Combs, 2009), (Cittadine, 2010), (Makower, et al., 2010) and for between 
25% and 50% of the cost that is normal within the industry (Shah, 2012), (Cittadine, 
2010), (Espicom, 2012) as shown from our business model (Griffiths, 2011), but also 
under the additional global economic and financial constraints of the last four years, I 
believe is compelling evidence in support of the claim that implementation of this 
innovation was achieved more effectively than is normal within the non-invasive 
medical device field.  
                                                            
39 Angel investor refers to an individual, not institutional, equity investor that does not take control or direct the 
management of the enterprise invested in. 
40 Institutional funding refers to traditional Venture Capital or Private Equity funding sources 
41 Less than $1 billion revenue 
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 4.2.2.4.2. Regulatory and reimbursement implementation effectiveness 
 
Espicom business intelligence points out that on average the regulatory approval 
timelines alone for non-invasive medical devices can range between two to seven years 
and costs approximately $2 million and $3 million for each major region sought; USA, 
Europe, Japan and China etc. (2012). The Topical Wound Oxygen therapy has not only 
achieved regulatory approval within the key segments, but within one year of attaining 
this prerequisite regulatory clearance has also achieved reimbursement within key 
market segments within the USA at a rate of approximately $3,300 per month of 
treatment (DEPARTMENT OF VETERANS AFFAIRS, 2009) and for no additional cost over 
that already outlined in the previous paragraph, which again supports the assertion that 
my implementation of this innovation was achieved more effectively than is normal. 
 
4.2.2.4.3. Clinical outcomes and healthcare cost saving implementation   
  effectiveness 
 
Worldwide, the direct reimbursement of all medical devices only accounts for about 5% 
of total healthcare spending compared to 70% for personnel and hospital organization 
costs (Espicom Health-care Intelligence, 2011). In the USA alone over $25 billion is spent 
annually on just the ongoing maintenance of chronic wounds (Centers for Medicare & 
Medicaid Services, Office of the Actuary, National Health Statistics Group, 2012), which 
equates to an average of about $4,400 per wound per year (Landers, 2008). Even at the 
$3,300 per month treatment cost, the successful implementation of this innovation 
does not significantly add to the cost of care, but to the contrary, should over time 
significantly decrease the ongoing costs of care for these patients. This will be achieved 
by a combination of the therapy’s ability to be utilized at home by the patient without 
the need for costly caregivers as described above, but also due to its ability to heal 
chronic wounds at between two to three times the rate and with much lower 
reoccurrence than with other treatment options42. Therefore, and as is supported by 
numerous physician testimonials (Frykberg, et al., 2012), each wound healed by this 
therapy would remove its annual ongoing cost burden, not to mention the 
improvements in morbidity, mortality and quality of life for the patients themselves43. 
Derk emphasizes this point in his paper on the topic, where he identifies the direct 
                                                            
42 The Innovation (TWO2) has been shown to completely heal chronic wounds at a greater than 80% rate at 12 
weeks compared to the between 30% and 40% rate of other therapeutic modalities (Derk, 2011) (Sultan & Tawfick, 
2010) (Blackman, et al., 2010) 
4339% to 80% of diabetic ulcer amputees will either die or have a second amputation within 5 years (Moulik, et al., 
2003) and over 30% will either die or have a second amputation within 2 years (Bruttocao, et al., 2011) 
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savings that TWO2 therapy provides, while achieving far greater healing outcomes at 
less than half the applied costs of the best alternate modalities (2011).  
 
When assessing the economic cost-effectiveness of an invention, one approach is to 
calculate the cost per incremental Quality Adjusted Life Years (QALY) and this is 
commonly used by payers as justification to pay for the innovation or treatment, a 
figure of $50,000 of incremental cost due to the intervention per QALY is a threshold 
often used in the USA and in the United Kingdom; NICE44 utilizes a value of about 
$45,000. (Steinbrook, 2008). QALY simply means a year of life lived in perfect health, so 
for someone with a disease that is not in perfect health you would modify this by a 
utility value, for instance for a patient with a non infected diabetic ulcer a utility factor 
of 0.75 is commonly used (Whitehead, et al., 2011), meaning that the cost of the 
intervention for 16 months would need to be below the thresholds amount detailed 
above to be deemed cost-effective. So to calculate the cost effectiveness of TWO2 
therapy we should first look at the total therapeutic costs to heal an ulcer and then the 
length of ulcer closure. The reimbursed cost for the therapy in the USA is $3,300 per 
month and an average conservative time to complete closure of a chronic ulcer as 
demonstrated in various publications is three months, so the total incremental cost of 
the innovation to heal a wound is approximately $9,900 (Derk, 2011). Clinical studies 
indicate that these ulcers remain closed for at least 3 years post closure (Blackman, et 
al., 2010) (Sultan & Tawfick, 2010). Therefore the cost per QALY is; $9,900 / 3 years X 
0.75 utility factor = $2,475 per QALY. If we compare this to the cost per QALY of other 
alternate therapeutic modalities; $27,310 for Full Body HBO (Chow, et al., 2008), €24 
881 for Negative Pressure Wound Therapy (Whitehead, et al., 2011) , which have lower 
efficacy (closure) rates and much greater reoccurrence rates (WILD, et al., 2010) 
(Cavanagh, et al., 2005), we see that TWO2 is far more cost-effective than these 
alternate therapeutics.  
 
Utilizing the proven positive impact on healthcare outcomes, cost of care reduction and 
the potential for the innovation to save the healthcare system millions of dollars over 
time as it is utilized, further supports the notion that this innovation not only has, but 
should continue to have, significant positive impact in the wound care arena and that its 
implementation being far more effective than is normal for therapeutic products within 
the field.  
 
                                                            
44 National Institute for Clinical Excellence (NICE) 
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4.2.2.4.4. Ethical implementation effectiveness 
 
The issue of ethics commonly comes up in healthcare, but is normally focused around 
clinical aspects and end of life decisions (Fox, et al., 2010). Over the last fifty years, the 
increasing life expectancy associated with better medical treatments and the resultant 
growing aging population driven by the baby boom generation,45 46 and the associated 
increases in people with chronic conditions, such as; diabetes and respiratory disease 
etc., has together created an enormous increase in the amount that countries spend on 
healthcare. In the USA an incredible $2.6 Trillion or $8,400 per capita, that equates to 
18% of Gross domestic product (GDP), was spent on healthcare in 2010 and other 
westernized countries are not that far behind these ratios (Organisation for Economic 
Co-operation and Development , 2011). This demographic ticking time bomb coupled 
with an ever increasing array of treatment options, and the availability of new 
technologies and drugs, is part of the explanation for these spiralling costs. When you 
add into the mix the austere economic realities that world economies have faced since 
the 2008 economic downturn (Ernst & Young, Global Life Science Center, 2011), it’s 
clear that hard decisions need to be made as to where every healthcare dollar, or Euro, 
is spent. This raises an ethical dilemma for societies as to what care to fund and for 
whom. It also reinforces the premise that new healthcare innovations should address 
not purely clinical needs, but do so while offering an economic benefit, be it by lower 
cost of treatments or by an overall reduction in cost of care for the patient over time, 
something that my innovations under discussion have clearly achieved. 
 
One approach to help standardize care and rein-in costs, which has grown into a gold 
standard over the last decade, has been that of evidence based medicine, whereby the 
decisions to use and pay for a therapeutic modality is driven by empirical peer reviewed 
clinical evidence and not by historical practice standards or physician preferences 
(Mauck & Timmermans, 2005). This approach has standardized the care available to 
patients in many cases, not by necessarily convincing the treating physicians that an 
alternate treatment is not warranted, but by simply not funding modalities that do not 
reach the evidence based bar. Belsey et al. emphasize this point in their report on the 
subject, concluding that evidence based medicine since its emergence 15 years ago 
“have seen its adoption, alongside health economics, as the gold standard tool for 
commissioning and provision of health services, both in the UK and around the world” 
                                                            
45 The baby boom generation are those that were born after the 2nd world war and are reaching 65 years of age 
beginning now 
46 The numbers of persons 65 years or older are expected to double by 2030 and similarly grow in the EU and 
Japan (Administration on Aging, 2011).  
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(2009, p. 8). The problem with this system has been that this newer barrier to entry has 
only generally been applied to new therapeutics and not retrospectively to older ones 
that in many cases were just “grandfathered-in”,47 this has resulted in a dichotomy of 
what is, and what isn’t, reimbursed. Another major limitation of this approach is that 
even after jumping through all the hoops needed to gain regulatory clearance for a new 
innovation in each respective region around the globe, companies are then additionally 
required to provide unequivocal clinical evidence of measurably improved clinical 
outcomes to the various separate reimbursement bodies globally, in order for the new 
therapeutic to be funded and paid for. This by its very nature requires a company to 
conduct at least one, if not multiple, randomized prospective controlled clinical trials 
that show statistically significant48 improved clinical outcomes compared to existing 
standards of care. In the non-invasive medical device field these trials are not commonly 
required for regulatory approvals, so this becomes an additional and very significant 
hurdle for any small company to overcome (Kramer & Schulman, 2012), and which I 
elaborated on in greater detail in the previous chapter on barriers to entry.  
 
The main ethical dilemma that I believe has evolved as evidence based medicine has 
become the de-facto norm enforced rigorously by payers globally, is that many 
promising life-enhancing and potentially life-saving innovations never become available 
to the majority of patients that could benefit from them, as the companies that have 
developed them tend to be small and are unable to overcome this evidence based bar, 
either due to inadequate financing or/and  clinical trial knowledge, so therefore fail to 
gain reimbursement for their therapeutic and thus never implement the innovation fully 
into the marketplace, thereby depriving patients of potentially life altering treatments. 
It’s ironic that the acronym for the reimbursement body tasked with making coverage 
decision in the United Kingdom is ‘NICE’,49 as it clearly has a reputation for commonly 
saying ‘no’ and turning down coverage for new treatment modalities. (Steinbrook, 2008) 
Conversely, many larger companies, particularly drug and invasive device companies, 
where the costs of trials are far greater than those needed for non-invasive devices 
(Bollyky, et al., 2010), commonly decide for pure economic return on investment 
reasons not to pursue the innovation through all these stages of implementation, 
irrespective of the clinical impact it may have on the intended population, again 
                                                            
47 Grandfathered in means they retained their historical reimbursement and were not assessed to the new 
benchmark level 
48 Clinical trials used for reimbursement or regulatory clearance, must be well structured and randomized and their 
outcomes must meet minimal levels of statistical significance in order to be considered under evidence based 
medicine empirics. 
49 National Institute for Clinical Excellence (NICE) 
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depriving patients of potentially life altering treatments purely due to economic return 
reasons. 
 
As mentioned earlier, one approach companies utilize to help combat the high cost of 
randomized clinical trials, is to select less expensive countries to conduct these trials. 
This raises the question of whether this is ethical. In the cases of non-invasive medical 
devices, which are the focus of this thesis, these devices have already received the 
required regulatory approvals to be marketed and these trials are required solely to 
attain broader reimbursement. Therefore, as long as the devices that are the subject of 
the trial are available for use within the trial country, then this approach is completely 
ethical, as it only allows for broader potential access to the device within that market 
and others. Another complimentary approach is to gather clinical and health economic 
data from utilization of the approved device within organisations where reimbursement 
can be attained without randomized clinical trials, referred to as registry data. Again, as 
before, this approach is completely ethical as it supports observational clinical evidence 
gathering during therapeutic utilization within the afflicted patient population. 
 
I believe strongly that healthcare payers, be them public or private, and the healthcare 
companies that develop new innovations, both share in the responsibility of 
implementing clinically significant treatment modalities into their intended market 
segments as effectively as possible, so that the as many patients as possible can benefit 
from their outcomes. This is both an ethical and a social responsibility and ultimately 
should result in good financial return for the business as well. Ethics and business 
success are by no means mutually exclusive of each other. With this mindset, I have 
focused my current company on helping get the Topical Wound Oxygen therapy out to 
as many patients globally as quickly as possible such that we can save their limbs and 
sometimes their lives as well. Due to our efficient attainment of reimbursement already 
in key needy sectors of the USA chronic wound market, our therapy today has already 
been utilized to heal the wounds in over 1,000 patients50 in the USA alone and probably 
twice this amount globally as is supported by the figures in the strategic business plan. 
(Griffiths, 2011, p. 4) To help further support the ethical application of resources and 
logical efficiencies of care, I have also tried to get the message out and have presented 
and spoken at a number of conferences globally over the last five years as detailed in my 
CV and conference presentations (Griffiths, 2012), attempting to educate the healthcare 
community on the plights of chronic wound patients and the costs they impose on their 
healthcare systems, as well as the therapeutic options that are open to heal them.   
                                                            
50 Calculated from the prescription orders for the therapy within the USA and number of treatments and the 
duration of therapy provided  
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4.2.3. Inspiration 51 Ventilator Product Family and eVent Medical Ltd. 
 
Innovation Global Health Need 
Addressed 
Evidenced within/by  
Public Work 
Inspiration 
Ventilator 
Product Family 
 
eVent Medical 
Ltd. Company 
Need for Life Support 
Intensive Care ventilation that 
is more affordable and flexible 
to operate in the less 
developed countries and harsh 
environments encountered 
around the world.  
 
 
Inspiration ventilator patent 
(Griffiths & Daescher, 2006) 
 
Inspiration ventilator FDA 510 (k) 
marketing application and clearance 
( Food and Drug Administration, 
2002) 
 
eVent Medical Ltd. Strategic 
Business Plan (Griffiths, 2005)  
 
Entrepreneurial Company structure 
newspaper article (Lytle, 2005) 
 
eVent Medical Ltd. Quality System 
(Griffiths, 2001) 
 
 4.2.3.1. Which global health need was addressed? 
 
This earlier implemented innovation of mine is another public works example of an 
innovation that was implemented more effectively than is normal within the non-
invasive medical device field, the difference being in this case that it is in the Respiratory 
Care, and more explicitly the Intensive Care Ventilator, market segment, opposed to the 
Wound Care market segment for the previous example. The innovation and its 
effectiveness in the marketplace was not only significant back when it was released, but 
is still evident today as supported by the product line and the company’s continued 
success as demonstrated on its website (eVent Medical Inc., 2012).  
 
In this market it was clear that there was a need for a low cost and effective life support 
intensive care ventilator that was more affordable and flexible to operate in the less 
developed countries and the harsh environments encountered around the world. 
According to NCIIA52 millions of people die each year in developing countries from lack 
of access to ventilators; additionally, the U.S. has only 14% of the ventilators needed in 
the event of an influenza epidemic (2010). Marketstrat in their global ventilator market 
                                                            
51 Inspiration is a registered Trademark of eVent Medical Inc. 
52 NCIIA is the National Collegiate Inventors and Innovators Alliance 
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report points out that developing countries have an ever increasing demand for capable 
ventilators due to evolving healthcare systems, extensive medical facility building and 
greater prosperity (Marketstrat, Inc., 2011). Historically, the Intensive Care Units (ICU) 
ventilator market had been dominated by one of three major players; Puritan Bennett 
from the United States, Draeger and Gettinge (formerly Siemens) from Europe, and a 
multitude of smaller regional companies. Per the primary market research that I 
conducted as that is incorporated within the eVent Medical Ltd. Strategic Business Plan, 
the user cost of ICU high performance ventilators ranged on average between $27,000 
and $35,000 (Griffiths, 2005) and more recently Husseini reported that the average ICU 
ventilator cost was approximately $30,000 (2010, p. 2). Due to these high prices coupled 
with the requirement for these high performing products to have stable electrical and 
pneumatic gas sources, not commonly seen outside of the western world, these 
clinically needed ventilation modalities and performance capabilities were in many 
cases beyond the reach53 of many developing markets, despite their growing need. 
4.2.3.2. What was the innovation that addressed this need? 
 
Within my eVent Medical  Business Plan public works I detailed the Inspiration 
ventilator’s unique design, with it incorporating a ‘solid state pneumatics54’ and ‘internal 
battery driven compressor, and web-based monitoring (Mini-Web) technology’ (2005, 
pp. 3-5). These design features made the ventilator very compact, robust and also 
allowed it to operate independent of stable gas and electrical supplies. The product was 
also very easy to operate with an integral graphical user interface. The importance of 
enhanced and easier to use graphical interfaces, such as was provided by the mini web 
server web-based monitoring in this product, has still eluded many ventilator 
manufacturers to this day, as Seiver pointed out in his discussion on ventilation trends, 
in stating that; “a familiar, information-rich, insanely great interface” is something that 
most ventilator companies should still be looking to engineer. (2009, p. 54) 
 4.2.3.3. Was the innovation implemented effectively?  
 
I founded eVent Medical Ltd. with the intent to develop and implement into the market 
a unique low cost high performance ventilator technology, as there was, and still is, a 
clear need for a life support (ICU) ventilator that is more affordable and flexible to 
operate, especially in the less developed countries and harsh environments around the 
                                                            
53 Both financially and infrastructure support wise 
54 Solid state refers to a solid block where all the valves were mounted and gas pathways were channelled within, 
opposed to traditional “spaghetti’ type tubing seen in most ventilators. This made the product very robust and 
extremely compact. 
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world.  The Inspiration is a low cost flexible ICU ventilator that incorporates many high 
end clinical features, integral gas supply and revolutionary remote monitoring and 
control capabilities via an embedded mini-web server. Formation of new knowledge 
through the product’s innovative technology is detailed in my public works product 
patent (Griffiths & Daescher, 2006) and by this very nature in the products themselves. 
The patent was peer reviewed by experts, published and made available to the public 
via publications as evidenced by the USPTO public database (United States Patent and 
Trademark Office, 2012). I then drafted and submitted the application and achieved 
United States marketing clearance authorization ( Food and Drug Administration, 2002) 
this is publicly available via the Food and Drug Administration clearance database 
website (FOOD AND DRUG ADMINISTRATION, 2012) 
 
My public works eVent Medical strategic business plan (Griffiths, 2005) illustrates the 
entrepreneurial company structure that I established and which also acted as the 
roadmap for all stakeholders for the company and innovation development. This plan 
was reviewed, lived by and involved many stakeholders. The innovativeness of my 
approach is further supported by a newspaper article on me and the company written at 
that time (Lytle, 2005). 
 
The formation of an innovative company structure and product through the 
development cycle is evidenced by the eVent Medical Quality system and resultant 
Quality Manual (Griffiths, 2001) that met audit scrutiny and criteria for both USA-FDA 
and European-CE regulatory agencies quality system approvals. The effective 
completion of product development into manufacturing and release to sales is 
evidences by the Product datasheets (Griffiths, 2002)and the marketing clearance by the 
FDA in the USA. Successful Adoptance of the innovation is also evidenced by this and 
also the company’s initial sales performance for the product as detailed in its strategic 
plan (Griffiths, 2005, p. 37). Successful Implementation of the innovation is evidenced by 
the continued sales of the Inspiration product line over the last ten years, with the last 
five being under the Kobayashi umbrella (Kobayashi Pharmaceutical, Ltd. , 2007) 
(Kobayashi Pharmaceutical, Ltd., 2010).  Additionally, successful implementation is also 
evidenced by the number of new product line extension based around this core 
innovative technology platform that have been brought to market, as shown on the 
company’s current website. (eVent Medical Inc., 2012) 
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4.2.3.4. Was the innovation implemented more effectively than is normal in the 
  field?  
 
4.2.3.4.1. Organization and product implementation effectiveness 
 
When I formed eVent Medical Ltd. it was my first start-up venture, having previously 
worked for various conglomerates and corporations within the medical device field. In 
similar vein to my second start-up entity, AOTI Inc, described above, but at that time 
with far less knowledge and experience, I put in place a flexible diversified and quasi-
virtual organizational structure that allowed me to attract away from their corporate 
employers and bring on board proven experts in the core competencies needed to be 
successful. Unlike AOTI Inc., which was formed as an American company, eVent Medical 
Ltd. was incorporated in Galway, Ireland, in order to take advantage of the experienced 
ventilator manufacturing expertise that existed in the area and also to focus initially on 
CE mark approval that would provided the fastest required regulatory clearances to 
market the product to the intended market segments, namely; the lesser developed 
markets of globe. I then outsourced/contracted-out all the necessary ancillary support 
functions, as detailed in my strategic plan for the company (Griffiths, 2005). 
 
The company was formed with the intent to develop a new innovative intensive care 
ventilator based on core technology that I had envisioned from an early prototype 
concept that I had seen and that I believed could provide high end features with added 
flexibility and at a far lower cost than other products within the industry. This concept of 
developing products with the end market customer’s needs at the forefront, but also 
with the cost of purchase, ownership and operation being a driving factor, has been 
termed ‘Design to Value’as illustrated in Figure 5 below and as has been extensively 
elaborated on recently by Chilukuri and colleagues in their report titled ‘Design to value 
in medical devices’ and who go as far as to say that “As price pressures increase, medical 
device makers need to rethink product development processes” and “If medical device 
companies want to continue to make money as prices face continued pressure, their only 
option is to take cost out.” (2010, p. 1). This approach is one that I employed when 
starting eVent Medical over a decade ago and has proven to be paramount to the 
success of the Inspiration product line innovations ever since. 
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       Figure 5: Conjoint analyses from Design to value in medical devices (Chilukuri, et al., 2010) 
As the eVent Medical Ltd. Strategic Business Plan details, the resultant Inspiration 
ventilator family was developed and brought to market in less than three years and for a 
total capital investment of only 3 million dollars, which in this case was funded solely by 
friends-and-family financing55 and one distribution channel partner. (Griffiths, 2005) If 
we compare these cost to market implementation figures to those from the publications 
of (Makower, et al., 2010), Cittadine (2010), (Shah, 2012) and Ernst & Young (2011), that 
are related to industry norms for development timelines and capital investments. It is 
evident that I was successful in forming and funding eVent Medical; Ltd.., and then 
developed and implemented the Inspiration ventilator product line within the global 
marketplace, in less than half the time and for about a quarter of the cost that is normal 
within the industry, evidencing that my implementation of this innovation was also 
achieved more efficiently than is normal within the field. 
 
 4.2.3.4.2.  Clinical outcomes and healthcare cost saving implementation   
   effectiveness 
 
The Inspiration ventilator had meaningful impact on the intended ventilated patient 
market in that it provided extensive high end clinical features and added flexibility at as 
                                                            
55 Friends and family refers to raising money intrinsically from the business proprietors and immediate associated 
parties. 
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low as half the price of other products, thereby not only lowering traditional equipment 
costs, but also making the devices more economically viable in less developed markets 
and countries. This effect is clearly demonstrated in the eVent Medical Strategic Plan by 
the sales mix of products being distributed throughout the globe and with many sales 
into the lesser developed market segments (Griffiths, 2005, p. 26). 
 
The chart below from my eVent Medical Strategic Plan (Griffiths, 2005) illustrates the 
Price to Performance positioning of the Inspiration ventilators relative to competitive 
products in the marketplace at that time. As you can see, the Inspiration offered 
significant high-end performance capabilities at a price point of far lesser performing 
products, in most cases for as little as one third of the price of the leading brands.  
 
 
          Figure 6. Inspiration Ventilator Price vs Performance from Staregic Plan Public Works Page 24 
 
The average price point for a high performance ICU ventilator in the USA was estimated 
recently still to be approximately $30,000 (Al Husseini, et al., 2010) demonstrating that 
there has been no meaningful price erosion over the last 5 years and supporting the 
continued sales and relevance of the impact of this innovation within the market place.  
 
Two additional unique feature of the patented electro-pneumatic56 design of the 
Inspiration ventilator are its ability to utilize a novel gas named Heliox, which is a 
                                                            
56 Electro-pneumatic refers to the integration of the control and delivery of the gases utilized for breathing 
(commonly air and oxygen) with the electronic components and circuitry needed to control and monitor their safe 
delivery and the patient’s response to their delivery.  
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mixture of Helium and Oxygen, that that allows for easier ventilation of obstructed 
breathing airways and can facilitate weaning57 patients off the ventilator much quicker 
(Flynn, et al., 2010), (Venkataraman, 2006) and its ability to provide this within non-
invasive ventilation modes58. Dasta demonstrated that the incremental cost associated 
with ventilating a patient in an intensive care unit within the USA was $1,522 per day, 
and he summates that “Interventions that result in reduced intensive care unit length of 
stay and/or duration of mechanical ventilation could lead to substantial reductions in 
total inpatient cost” (2005, p. 1270). Therefore the capability of the Inspiration to help 
wean patients off the ventilator quicker provides additional operational cost savings to 
the healthcare community to those related directly to its lower purchase price. 
Extrapolating these savings out shows that based on a mid-range average sales price of 
the Inspiration ventilator of $10,000, that its total acquisition price could be offset 
entirely by just six patient ventilation days saved. This could be as one patient weaning 
of the ventilator six days earlier, or six patients each weaning one day earlier, or 
anything in-between.  
 
Combined, the continued market presence and success of the Inspiration innovation 
within the marketplace, the significant direct cost savings it provides related to its much 
lower purchase price and to the weaning reduction cost savings it can furnish, I believe 
strongly supports the concept that from a Clinical Outcomes and Healthcare Cost Saving 
standpoint that the innovation was implemented more effectively than is normal for 
products within the ICU ventilator marketplace. 
 
  
                                                            
57 Weaning in this case refers to the to the methodical sequential reduction in mechanical ventilator support of a 
patient’s breathing and the corresponding pick p in the patient’s breathing workload 
58 Non-invasive ventilation is ventilating patient via s mask or nasal prong, opposed to invasive ventilation, that 
involves inserting a tracheal tube into the patients airways or by creating a tracheotomy 
61 
 
4.2.4. 7250 Metabolic Monitor 
 
Innovation Global Health Need 
Addressed 
Evidenced within/by  
Public Work 
7250 Metabolic 
Monitor  
Inaccurate measurements of 
metabolic demands/needs of 
ventilated patients within 
Intensive Care Units result in 
dangerous under feeding, 
overfeeding or imbalanced 
substrates. 
Technical Metabolic Monitor 
Handbook (Griffiths, 1996) 
 
Clinical Metabolic Monitor 
Handbook (Griffiths, 1996) 
 
My involvement in the market development and management of the 7250 Metabolic 
monitor was one of my earliest examples of implementing an innovation into the 
Respiratory care field. In this case it was the stewardship as the product manager of an 
innovative product for which I was responsible within a multi-national corporation. 
 
4.2.4.1. Which global health need was addressed? 
 
Inaccurate measurements of metabolic demands/needs59 of ventilated patients within 
Intensive Care Units results in dangerous; under feeding, overfeeding or imbalanced 
substrates60, resulting is extended ventilation days and costs, or more serious clinical 
outcomes. (Faisy, et al., 2003). Historical metabolic monitors had been ineffective and 
inaccurate in ventilated patients. The problem was these measurement were inherently 
difficult to obtain and the values taken on a spot check bases did not track true 
metabolism as the patient’s clinical condition varied over time, resulting commonly in 
dangerous overfeeding, underfeeding and inadequate ventilator support.  
 
4.2.4.2. What was the innovation that addressed this need? 
 
The unique technology provided easy real-time continuous measurements of these 
previously described parameters, and along with that with an entered urine urea value 
(representing nitrogen metabolism) the actual breakdown of substrate metabolism for 
the patient.  This provided unheralded accuracy in the adjustment of the nutritional 
                                                            
59 Metabolic monitoring traditionally refers to a spot-check measurement of a patient’s Oxygen Consumption (VO2) 
and Carbon Dioxide production (VCO2)production, which when divided by each other gives you the Respiratory 
Quotient (RQ) and can be used to calculate the total Resting Energy Expenditure (REE), which is a measurement of 
total caloric needs.  
60 Substrates being the mix of Protein Fat and Carbohydrates the body metabolizes 
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support of the ventilated patient in terms of total caloric needs and substrate mix, as 
well as appropriate ventilator settings management 
 
The 7250 Metabolic Monitor significantly improved how many ventilated patients are 
metabolically managed by proving accurate measurements of the patient’s nutritional 
needs and metabolic work rate. This allowed clinicians to accurately tailor therapy to 
these needs, opposed to just utilizing inaccurate predictive equations. The public works 
examples; technical (Griffiths, 1996) and clinical handbooks (Griffiths, 1996), were 
instrumental in educating clinicians and biomedical engineers as to the problem 
associated with traditional measurement techniques and how this new innovative 
technology overcame such issues, it also outlined how to interpret and utilize this new 
information.  
 
4.2.4.3. Was the innovation implemented more effectively than is normal in the 
  field?  
 
The Clinical (Griffiths, 1996) and Technical (Griffiths, 1996) metabolic handbooks were 
written and made freely available to the respiratory care profession and disseminated 
new knowledge, ideas and clinical approaches to the field. The detailed research, new 
concepts and resultant metabolic product development outlined in these texts 
supported the adoptance into the ventilator market place of the 7250 metabolic 
monitor. This adoption resulted in improved patient care and outcomes in a growing 
number of clinical conditions Successful and meaningful Implementation of the 
innovation is evidenced in its continued utilization over the last fifteen years across a 
widening gambit of conditions, as demonstrated in numerous published clinical papers 
citing its use over the last decade; (Reid, 2007) (Faisy, et al., 2003), (Miwa, et al., 2003). 
(Brandi, et al., 1999), (Barco, et al., 1998) 
 
This innovation was developed while I worked for a corporation and was therefore one 
development project amongst many that this medium sized ($300 million annual 
revenue) company had ongoing at the time. Like is common with many product 
development projects, this project was assessed at various stages of development as to 
its continued viability. This assessment was based around the potential return on 
investment to the company and other strategic initiatives the company had at that time 
and which over the course of the development changed significantly.  Despite all this 
and the declining financial position of the company, which caused the development 
team to be downsized on numerous occasions, the 7250 metabolic monitor was 
developed and released to the marketplace in less than four years and due to its small, 
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but dedicated and focused development team, for a minimal amount of capital expense 
allocation from the corporation. When this is compared to the timeline and cost norms 
for the industry established earlier, they support the claim that the implementation of 
this innovation was also achieved more efficiently than is normal within the field. 
 
4.3. Summary of the overall impact of the implementation of innovation from my 
public works  
 
In the previous section of this chapter I have conducted a detailed evaluation and 
analysis of three of my public works that I believe best validate my claim of making 
unique contributions that have had significant impact within my area of expertise and 
that show specifically that I have implemented Innovation more effectively within the 
highly regulated non-invasive medical device field. However, as I have detailed 
throughout this context statement, my public works as a whole encompasses more than 
just these three examples. Therefore, it is pertinent I believe to synthesize my public 
works in their entirety in order to assess how they support my claim and the overall 
contributions that I have made to the sector.  
 
Progressively throughout my career within this specialized sector, I have directly 
engaged in advanced work based learning that has taken many forms that has been 
interdisciplinary in nature. The impact of this on my professional development is 
summarized within my detailed CV (Griffiths, 2012) and highlights my increasing 
professional responsibilities, career evolution, expanding academic and clinical 
credentials and extensive history of lecturing and speaking engagements. These varied 
roles have required me to analyze and overcome numerous complex problems, many of 
which have been unforeseen, and conceptualize multiple work-based projects that have 
required extensive methodological research, that have resulted in new ideas, new 
approaches and my cited public work results. Examples of which include my three public 
works explored in great detail in the section above. This impact is also further supported 
by the day to day operation and strategic stewardship of the companies, eVent Medical 
Ltd. and AOTI Inc., that I formed and ran within the sector and which continue to thrive 
today, despite all the economic turmoil we have faced in the last decade, and as 
evidenced by their company webs sites (AOTI Inc., 2012) (Griffiths, et al., 2012) and 
annual reports (Kobayashi Pharmaceutical, Ltd., 2010) and by our dealer testimonials 
(USA and International Distributors, 2012). I have contributed an array of work related 
projects that have been quite varied in nature, but that in many cases have added new 
knowledge to the field. I have been an advanced educator, having conducting numerous 
presentations globally, and have developed a number of new educational materials and 
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manuals as demonstrated by my public works conference presentations (Griffiths, 1995 
- 2012) and pre-study manuals (Griffiths & Canfield, 1993) etc. I have been an Inventor, 
developing a number of new technologies as evidenced by my patents in both the 
ventilator (Griffiths & Daescher, 2006) and wound care (Griffiths, et al., 2009) arenas. I 
have also been an entrepreneurial company founder and operational executive, as 
supported by my various company strategic plans for both eVent Medical Ltd. (Griffiths, 
2005) and AOTI Inc. (Griffiths, 2011), as well as in local newspaper articles (Lytle, 2005) 
and press releases (Doyle, 2010).  
 
Additionally, these combined public works outputs not only demonstrate attainment of 
my claim, but also how I have utilized my learning in daily practice and have contributed 
to my field of expertise, that when combined with the learning and gained expertise 
that I have attained over two and a half decades, has furthered my standing within the 
industry and allowed me to be viewed as a subject matter expert by my peers, which is 
evidenced within my detailed CV (Griffiths, 2012) by my varied speaking engagements, 
professional society memberships and fellow designation.  
 
Throughout all of these endeavours there is a common thread that I believe solidifies 
my contributions, being that I have focused on implementing meaningful product 
innovations61 and creating business structures that are more effective than is normal 
within this sector. By this I mean that I have identified, developed, and invented 
products that address real world needs, with an awareness of the ethical and economic 
dilemmas that we face in the healthcare community today. This requires focusing not 
solely on the clinical benefits of the innovations, but also on their overall economic 
impact and the benefits they purport to bring to the healthcare system as a whole. I 
have achieved this outcome by forming new entrepreneurially structured entities that 
have implemented these innovations into the global market place faster and for far less 
cost than is the norm for the sector, all of which is evidenced again by my three public 
works products detailed previously in this chapter associated with; the Topical Wound 
Oxygen Therapy and AOTI Inc. (Griffiths, 2011), the Inspiration Ventilator product line 
and eVent Medical Ltd. (Griffiths, 2005), and the 7250 Metabolic monitor (Griffiths, 
1996). Within each of these different public works examples I have demonstrated more 
effective implementation in  a number of the required aspects, including those of; 
organizational structure, regulatory approval and reimbursement attainment, product 
and clinical outcomes, and healthcare system cost saving. 
 
                                                            
61 These include technological product innovations as are detailed in the earlier sections of this chapter, but also 
educational and methodological innovations as discussed throughout the thesis. 
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I believe that the single most significant legacy related to my claim is that associated 
with the positive clinical-economic healthcare impact that the Topical Wound Oxygen 
Therapy product line has and will continue to provide to global healthcare systems. 
Clinically, this implemented innovation has been demonstrated to completely heal 
recalcitrant ulcers at unprecedented efficacy ratios of greater than 80%, as evidenced by 
numerous published clinical studies (Frykberg, et al., 2012), (Japour, et al., 2012), (Sultan 
& Tawfick, 2010), (Blackman, et al., 2010) to cite a few. Economically, and as I have 
detailed earlier in this chapter, this therapy achieves these clinical outcomes for far less 
applied cost than any other therapeutic modality of far lower efficacy. When combined 
with the incredibly low wound reoccurrences also evidenced in these clinical trials, the 
ultimate result will be significantly reduced ongoing healthcare costs associated with 
these chronic epidemically growing conditions. 
 
4.4. Pragmatic Entrepreneurship and Best Practice recommendations 
 
The pragmatic entrepreneurship approach that I have refined over two decades as a 
practitioner within my field of expertise and which I have elaborated on within the 
preceding discussions about my public works, provides insight into some best practice 
recommendations that may be useful to others within the medical device field and in 
other industries as well.  My approach and model is contingent on a number of iterative 
but interdependent phases that grow on each other and that are intended to allow for 
faster transition through the various stages of implementation for the innovation, these 
can be summarized by the stages and in the diagram that follow: 
 
1. This initial grounding phase is identifying and understanding a clear proven 
user/market need that is underserved by existing solutions. 
 
2. This need then directs the focused development of innovative solutions, be them 
completely new ideas, or a modification of existing ideas or technology.  
 
3. The next step is the establishment of a lean organizational structure capable of 
implementing the innovation. The focus here must be on talent and expertise 
and not location, with careful selection of trusted, known, competent individuals 
for the core functional areas required and that can work independently.  
 
4. Where possible, outsource expensive infrastructure such as manufacturing to 
experts in the respective activity, but always provide management oversight of 
these critical functions to guarantee quality, as this minimizes capital needs and 
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more effectively achieves scalability as the business grows.  
 
5. The regulatory and follow on marketing strategy should focus on the 
development of all global markets in parallel, in order to maximize both the 
business opportunity, ethical clinical impact and to provide revenue earlier.  
 
6. Throughout the stages always reassess progress and adapt to changing 
regulatory and reimbursement landscapes and changing market needs. 
 
7. Where possible align raising funds to minimize dilution. Exploit easier and more 
accessible funding, such as friends and family and angel investors, rather than 
larger time-consuming and more dilutive venture capital rounds. Do not 
underestimate capital raising time requirements and complexities. 
 
 
                     Figure 7.  Pragmatic Entrepreneurship Model  
 
To effectively utilize this model it is critical that the entrepreneurial leader have the 
skills to both manage and motivate geographically dispersed team members. This 
should include minimal but adequate reporting structures, clear dissemination and buy-
in to the strategic vision for the entity, and where possible, performance based equity 
type compensation. The importance of these facets should not be underestimated if the 
venture is to be a success.   
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5. Conclusions and Reflections 
 
As I have outlined in the preceding sections, I am an established industry professional 
that has progressively attained greater levels of responsibility and professional standing 
over a long career in the medical device industry. My body of public works is a 
combination of pertinent examples from this period, that I believe when assessed in 
their entirety demonstrate that I have not only contributed to, but have significantly 
affected, daily practice by implementing innovation more effectively within the non-
invasive medical devices field.  
 
I have repeatedly engaged directly in advanced work based learning that has taken 
many forms and that has been clearly interdisciplinary in nature. Although, there has 
been one common theme, that being the medical device industry, and more specifically, 
the Respiratory and Wound Care segments of that industry. I have been an advanced 
educator, an inventor, a product developer, a product and marketing manager, an 
operational executive and an entrepreneurial company founder, all within this 
specialized sector. These varied roles have required me to analyze and overcome a 
considerable number of complex problems and obstacles, many of which have been 
unforeseen, requiring me to conceptualize multiple work based projects involving 
extensive methodological research, that in many cases have resulted in new ideas and 
new approaches as evidenced by the public work examples summarized within this 
context statement. The outputs of these projects have been quite varied, but have in 
many cases added new knowledge to the field, but uniformly have incorporated a 
tangible real world context and work based aspect.  
 
Overcoming the many varied obstacles that I have encountered over the years has 
necessitated the development of a unique set of skills, encompassing the many 
technological, clinical and management aspects of my profession. In honing these skills, 
it has taught me to evolve my approach in analyzing and addressing challenges by calling 
on my work based learning and the life lessons learnt. As I have become more 
experienced in implementing innovation, I have developed a very pragmatic approach 
to problem solving that always includes a real world needs assessment sanity check, 
which allows me to clearly envision innovative solutions and create unique 
organizational structures to implement them more effectively. The learning and gained 
expertise attained through this iterative process has also allowed me to reach the 
highest leadership level within my profession and to be viewed as a subject matter 
expert by many of my peers.  
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Within the preceding chapter I have focused my analysis of my public works to three 
prominent examples of technological innovations addressing distinct real world global 
health needs that I implemented more effectively and utilizing innovative organizational 
structures and which I believe best illustrate my claim. However, additionally 
throughout my context statement I have touched on numerous other public works 
examples that demonstrate my accumulative workplace driven knowledge attainment, 
its impartment and the resultant impact to my field of expertise in the many 
professional areas that I have had the privilege to practice and contribute These include 
such areas as; teaching and education, subject matter presentations, organizational 
leadership and pragmatic entrepreneurship, admittedly them likely being less impactful 
individually to my specific claim than those public works examples that I focused on in 
my analysis. When combined though, these works demonstrate a continuous theme 
that I have had significant impact in both my professional development and the efficacy 
of my professional standing. This body of public works in its entirety also demonstrates 
how I have utilized my learning in daily practice and how I have contributed significantly 
to my field of expertise with advanced new innovations and knowledge and specifically 
demonstrates a proven documented commitment to, and of having, implemented 
innovation more effectively within the non-invasive medical device field. 
 
Furthermore, I strongly believe in, and as I believe my public works examples 
demonstrate, that I have contributed positively to the ethical implementation of 
technological innovations into the global healthcare arena. This is critical in my eyes, as 
the growing global tsunami in the costs associated with providing acceptable levels of 
healthcare that we are all faced with can only somewhat be averted by the intelligent 
allocation of existing resources and technology. The demographic changes are 
undeniable and unchangeable and with them the associated rise in people suffering 
from debilitating chronic diseases will not abate solely due to our lack of financial 
resources to deal with them. Without question improvements in prevention of these 
diseases and educating people on lifestyle changes to lessen their likelihood of 
developing them is paramount to the strategy. Even with this though, our societies as a 
whole will be faced with increasingly difficult decisions related to the rationing of 
healthcare. We must all do our part in reducing cost of care, be we in the policy making 
realm, industry, or healthcare provision arenas. More cost effective treatment 
modalities is one area where we can help, but clearly by moving care, where feasible, 
away from costly care sites such as hospitals and medical centres, is the most significant 
way to impact these cost moving forward, as only 70% of the costs are associated with 
manpower and infrastructure related items. I am most proud that my most significant 
contributions to the field detailed previously have all been associated with not just 
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clinical and patient quality of life improvements, but equally, in meaningfully 
contributing to reducing direct and ongoing healthcare costs related to the afflictions 
that they treat, this I believe is the essence of pragmatic entrepreneurship.  
 
I would like to point out that I have found the entire process required to construct a 
coherent context statement rather exhausting at times but ultimately incredibly 
liberating. The level of reflection required to assess my claim has been intensive, not 
just as it relates to the public works materials themselves, but equally as it relates to 
myself and inner psyche. I feel like I have grown enormously because of the process, 
have honed my academic skills and feel even greater command of my professional 
abilities. I am passionate now to take these new entrepreneurial skills forward and 
continue to impact the community as positively as I can. 
 
 
 
Word count: 24,410 
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